35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
24 April 2026, Friday	13:40 - 15:10	1327	APASL - IASL JOINT MEETING	Zhe Dai	VDAC1-ACSL3-mediated aberrant lipid droplet-mitochondria crosstalk to promote HCC in CHB and MASLD coexistence
24 April 2026, Friday	13:40 - 15:10	1726	APASL - IASL JOINT MEETING	Xinrong Zhang	Glucagon-like peptide-1 receptor agonists and reduced liver and non-liver complications in patients with type 2 diabetes and viral hepatitis
24 April 2026, Friday	13:40 - 15:10	2785	APASL - IASL JOINT MEETING	Huan Cheng Cheng	Metabolic Dysfunction Increases the Risk of Liver-related Events in Virologically Suppressed HBV Related Compensated Cirrhosis: Refining Prognostication with the Baveno VI-SSM Model
23 April 2026, Thursday	07:30 - 08:30	1067	ORAL PRESENTATION 01	SREEJITH OZHUKIL THEVARKALATHIL	Clinical Profile and Short-Term Outcomes of Patients with Acute-on-Chronic Liver Failure: A Prospective Observational Study from a Tertiary Center in Southern India
23 April 2026, Thursday	07:30 - 08:30	1079	ORAL PRESENTATION 01	Ngan Le Thanh Quynh	Prognostic utility of the MELD score and AE model in predicting acute-on-chronic liver failure among patients with severe acute exacerbation of chronic hepatitis B.
23 April 2026, Thursday	07:30 - 08:30	1189	ORAL PRESENTATION 01	YAO ZHANG	VISTA deficiency exacerbates the development of acute-on-chronic liver failure by promoting Tc1 Differentiation
23 April 2026, Thursday	07:30 - 08:30	1201	ORAL PRESENTATION 01	Bandar Aljudaibi	Outcomes of Living Donor Liver Transplantation in Patients with or without Acute-on-Chronic Liver Failure: A Single Centre Experience
23 April 2026, Thursday	07:30 - 08:30	1239	ORAL PRESENTATION 01	xueshi zhou	Study on the Value of Antithrombin III Activity Combined with COSSH-ACLF Score in Predicting the Prognosis of HBV-ACLF Patients in the Intensive Care Unit
23 April 2026, Thursday	07:30 - 08:30	1252	ORAL PRESENTATION 01	Dr Kapil Kumar Kumar	Clinical Trajectories of Acute Decompensation in Cirrhosis: The First Prospective PREDICT-Based Study from India
23 April 2026, Thursday	07:30 - 08:30	1338	ORAL PRESENTATION 01	Jingjing Chen	Validation of the 2025 Global Expert Panel Consensus Definition of ACLF in Real-World Hospitalized Patients With Cirrhosis
23 April 2026, Thursday	07:30 - 08:30	1384	ORAL PRESENTATION 01	Tatsuo Kanda	Hepatitis A and E Guidelines created by the Japan Agency for Medical Research and Development (AMED) HAV and HEV Study Group
23 April 2026, Thursday	07:30 - 08:30	1385	ORAL PRESENTATION 01	Pengfei Yu	Direct chemical reprogramming of urine-derived stem cells from acute-on-chronic liver failure patients into hepatocyte-like organoids to attenuate liver injury
23 April 2026, Thursday	07:30 - 08:30	1156	ORAL PRESENTATION 02	Qiao Wei	Contrast-enhanced Ultrasound Features of Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC): A Case Series Report
23 April 2026, Thursday	07:30 - 08:30	1179	ORAL PRESENTATION 02	MANISH KUMAR	Association of Urinary Spot Sodium-Potassium Ratio with Acute Kidney Injury in Decompensated Cirrhosis
23 April 2026, Thursday	07:30 - 08:30	1335	ORAL PRESENTATION 02	Adela Turcanu	A 7-item discharge risk index predicts 12-month decompensation in HDV cirrhosis: derivation and external validation
23 April 2026, Thursday	07:30 - 08:30	2742	ORAL PRESENTATION 02	Jasmohan Bajaj	PREDICTION OF NOSOCOMIAL INFECTION DEVELOPMENT REMAINS SUBOPTIMAL DESPITE USING MACHINE LEARNING TECHNIQUES IN A PROSPECTIVE GLOBAL COHORT OF HOSPITALIZED CIRRHOSIS PATIENTS
23 April 2026, Thursday	07:30 - 08:30	2789	ORAL PRESENTATION 02	SHREYAS SARVESH	Comparison of the Safety and Efficacy of Tailored versus Fixed-Dose Albumin in Cirrhosis with Sepsis-Associated Acute Kidney Injury: A Randomised Controlled Trial
23 April 2026, Thursday	07:30 - 08:30	2841	ORAL PRESENTATION 02	Fan Li	PLPP2 drives liver repair and regeneration via remodeling phosphatidylethanolamine metabolism after acute liver injury
23 April 2026, Thursday	07:30 - 08:30	2879	ORAL PRESENTATION 02	Jaifrin Daniel	AARC score predicts survival in patients with Acute on Chronic Liver Failure due to Severe Alcoholic Hepatitis undergoing Plasma Exchange
23 April 2026, Thursday	07:30 - 08:30	2894	ORAL PRESENTATION 02	Sudhir Verma	Splenic probe (100 KPa) is superior to liver probe (75 KPa) in assessment of liver stiffness and predicting outcomes in Acute on chronic liver failure patients
23 April 2026, Thursday	07:30 - 08:30	1140	ORAL PRESENTATION 02	Liying Ren	EEF1E1 sustains EGFR signaling to drive immune evasion and tumor progression in hepatocellular carcinoma
23 April 2026, Thursday	07:30 - 08:30	1126	ORAL PRESENTATION 03	Helin ÖZALKAN	Development of a Dual-Module Artificial Intelligence System for Non-Invasive Staging of Liver Fibrosis Using Blood Tests and Ultrasound Images
23 April 2026, Thursday	07:30 - 08:30	1127	ORAL PRESENTATION 03	Beyzanur BAYIR	Development of a Multi-Modal Artificial Intelligence Assistant for Early Diagnosis of Hepatocellular Carcinoma Using Imaging and Laboratory Data
23 April 2026, Thursday	07:30 - 08:30	1157	ORAL PRESENTATION 03	Jialin Chen	Predictive Model for Targeted Combination Immunotherapy Efficacy in Unresectable Hepatocellular Carcinoma Patients Based on Multimodal MRI Radiomics (MC-hccAI 007): A Multicenter Study
23 April 2026, Thursday	07:30 - 08:30	1278	ORAL PRESENTATION 03	Mucong Yu	Small lesion oriented early hepatocellular carcinoma segmentation via a hybrid-attention deformable U-Net
23 April 2026, Thursday	07:30 - 08:30	1341	ORAL PRESENTATION 03	Engin Altınkaya	Screening of new active molecules derived from ursodiol in the treatment of primary biliary cholangitis and ursodeoxycholic acid
23 April 2026, Thursday	07:30 - 08:30	1476	ORAL PRESENTATION 03	Chuan Pang	Prediction of microvascular invasion in HCC using spatiotemporal radiomics of contrast-enhanced ultrasound: a deep learning model with tumor microenvironment correlation
23 April 2026, Thursday	07:30 - 08:30	1785	ORAL PRESENTATION 03	Cong Wang	Automatic Detection of Hepatocellular Carcinoma on MRI Using a Lesion-Aware Fine-Tuning Framework
23 April 2026, Thursday	07:30 - 08:30	2268	ORAL PRESENTATION 03	Haoran Sun	Interpretable AI That “Reads the Liver From the Face”: A 3D-Face Digital Biomarker for Ultrasound-Confirmed NAFLD
23 April 2026, Thursday	07:30 - 08:30	2300	ORAL PRESENTATION 03	Mehmet Yıldız	Old Drugs, New Targets: Repurposing Proton Pump Inhibitors for Autoimmune Liver Diseases: Molecular Docking Insights into the TLR4/MD-2, NLRP3, and C5aR1 Axes
23 April 2026, Thursday	07:30 - 08:30	1238	ORAL PRESENTATION 04	Hasan Eruzun	Awareness of Primary Biliary Cholangitis Among Turkish Physicians: An Online Survey
23 April 2026, Thursday	07:30 - 08:30	1263	ORAL PRESENTATION 04	Yusuf Bünyamin Ketenci	The Paradox of Size: A Non-Linear Relationship Between Liver Size and Fibrosis Stage in Acute Autoimmune Hepatitis
23 April 2026, Thursday	07:30 - 08:30	1447	ORAL PRESENTATION 04	Ahad Eshraghian	N acetyl cysteine plus corticosteroid versus corticosteroid alone for treatment of acute severe autoimmune hepatitis: a randomized clinical trial
23 April 2026, Thursday	07:30 - 08:30	1768	ORAL PRESENTATION 04	Chao Cai	ALT Trajectories Differentiated by Early Treatment Response Determine Long-Term Outcomes in Autoimmune Hepatitis
23 April 2026, Thursday	07:30 - 08:30	1775	ORAL PRESENTATION 04	Wenxuan Shang	Longitudinal Analysis Reveals Comparable ALT Trajectories and Achievement of Biochemical Remission Regardless of Baseline Fibrosis in Autoimmune Hepatitis
23 April 2026, Thursday	07:30 - 08:30	1883	ORAL PRESENTATION 04	Christine Velasquez	Early-Onset PSC With Recurrent Cholangitis Requiring Early Transplant Evaluation: A Five-Year Case Trajectory and Prelude to the Transplant Course
23 April 2026, Thursday	07:30 - 08:30	2148	ORAL PRESENTATION 04	YunLong Yao	B-Cell Depletion Therapy Shows Efficacy in Steroid-Refractory Autoimmune Hepatitis
23 April 2026, Thursday	07:30 - 08:30	2433	ORAL PRESENTATION 04	Mubin Ozercan	Diagnostic performance of non-invasive fibrosis scores in treatment-naïve patients with autoimmune hepatitis
23 April 2026, Thursday	07:30 - 08:30	1197	ORAL PRESENTATION 05	Ling Xu	Enhancement of Liver Regeneration in Mice through DDX3X-CD36 Pathway-Mediated Promotion of Hepatic Lipid Accumulation
23 April 2026, Thursday	07:30 - 08:30	1266	ORAL PRESENTATION 05	Liwei Zeng	The quality and reliability of short videos about liver cirrhosis on Bilibili and TikTok: Cross-sectional study
23 April 2026, Thursday	07:30 - 08:30	1311	ORAL PRESENTATION 05	Danish Ahmed	Liver-Centric Therapeutic Profiling of 2β-Hydroxybetulinic Acid-3β-Caprylate (HBAC): A Phyto-Derived Modulator of Hepatic Redox Balance, Gluconeogenesis and Lipotoxic Stress in Experimental Diabetes
23 April 2026, Thursday	07:30 - 08:30	1336	ORAL PRESENTATION 05	Tushar Prabhakar	Can poor sleep signal fatty liver disease? Evidence from a rural population in North India
23 April 2026, Thursday	07:30 - 08:30	1387	ORAL PRESENTATION 05	Chaiyaboot Ariyachet	The transcription factor PRDM5 is a novel pro-fibrotic factor in liver fibrosis
23 April 2026, Thursday	07:30 - 08:30	1559	ORAL PRESENTATION 05	Xue Zhang	SIRPA as a Novel Regulator of T Cell Apoptosis in Hepatocellular Carcinoma: Implications for Immunotherapy
23 April 2026, Thursday	07:30 - 08:30	1679	ORAL PRESENTATION 05	Naseer Kawish	PASSIVE TOBACCO SMOKE INDUCED CHANGES IN THE EXPRESSION OF IRON METABOLISM GENES IN MOUSE PUPS
23 April 2026, Thursday	07:30 - 08:30	1783	ORAL PRESENTATION 05	Soner KARABULUT	LLGL1 Loss Attenuates Hippo Signaling and Sustains Pro-oncogenic YAP Activity in Hepatocellular Carcinoma Cells
23 April 2026, Thursday	07:30 - 08:30	1836	ORAL PRESENTATION 05	Jingran Jiao	Trends in hepatitis B-related diseases in Asia, 1990-2023: an analysis of the Global Burden of Disease 2023 update
23 April 2026, Thursday	07:30 - 08:30	1708	ORAL PRESENTATION 06	Xiaoxiao Wang	Males are emerging as the primary high-risk population for gallbladder and biliary tract cancers
23 April 2026, Thursday	07:30 - 08:30	1909	ORAL PRESENTATION 06	Cleo Christille Lynn Lom-oc	A Diagnostic conundrum in a Case of Obstructive Jaundice in Biliary Hamartoma
23 April 2026, Thursday	07:30 - 08:30	2145	ORAL PRESENTATION 06	Ahmet Uyanikoglu	Gestational cholestasis: single center experience
23 April 2026, Thursday	07:30 - 08:30	2395	ORAL PRESENTATION 06	Zhigang Ren	Multicohort fecal metagenomes analysis contributes to non-invasive diagnosis for cholangiocarcinoma
23 April 2026, Thursday	07:30 - 08:30	2439	ORAL PRESENTATION 06	Abdullah Tanrıkulu	A silent threat: A case of infiltrative cholangiocellular carcinoma developing withouth detectable mass
23 April 2026, Thursday	07:30 - 08:30	2518	ORAL PRESENTATION 06	shasha li	Antinuclear Antibodies Positivity Indicates a High-inflammatory Phenotype in Primary Biliary Cholangitis: A Multicenter Retrospective Analysis
23 April 2026, Thursday	07:30 - 08:30	2596	ORAL PRESENTATION 06	Phool Chand	Baseline Determinants of Inadequate Ursodeoxycholic Acid Response in Primary Biliary Cholangitis: A POISE-Based Real-World Cohort Study
23 April 2026, Thursday	07:30 - 08:30	1346	ORAL PRESENTATION 07	Gabriel Daniel Alcantara	A Ductless Dilemma: Pembrolizumab Induced versus Paraneoplastic Vanishing Bile Duct Syndrome
23 April 2026, Thursday	07:30 - 08:30	1362	ORAL PRESENTATION 07	Xiaoyu Huang	Cell-Microcapsule-Loaded Potent Nanoenzymes Alleviate Drug-Induced Liver Injury via Dual Strategies
23 April 2026, Thursday	07:30 - 08:30	1656	ORAL PRESENTATION 07	Suwen Jiang	Analysis on the differences of clinicopathological characteristics in drug-induced liver injury patients with positive or negative autoantibodies and different clinical types
23 April 2026, Thursday	07:30 - 08:30	1722	ORAL PRESENTATION 07	Jasmin Gondayao	Paraneoplastic Hyperbilirubinemia in Hodgkin’s Lymphoma: An Uncommon Presentation with Significant Diagnostic and Therapeutic Challenges
23 April 2026, Thursday	07:30 - 08:30	2125	ORAL PRESENTATION 07	Yong Liu	Efficacy and Safety of Magnesium Isoglycyrrhizinate in Checkpoint Inhibitor-Induced Liver Injury in Patients with Advanced Solid Tumors: An Exploratory Study
23 April 2026, Thursday	07:30 - 08:30	2604	ORAL PRESENTATION 07	Hua Liu	Research on artificial liver support system for non-hepatocellular carcinoma patients with severe immune checkpoints related liver injury

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
23 April 2026, Thursday	07:30 - 08:30	2606	ORAL PRESENTATION 07	Rongtao Lai	A Simple Five-Variable Model Integrating GWAS Variants Predicts Chronic Outcomes in Drug Induced Liver Injury
23 April 2026, Thursday	07:30 - 08:30	2814	ORAL PRESENTATION 07	Duygu Birinci	Etiological distribution, clinical phenotypes and six-month outcomes of drug-induced liver injury: a single-center cohort study
23 April 2026, Thursday	07:30 - 08:30	1133	ORAL PRESENTATION 08	Xueyan Lin	A Novel HFE Mutation C.1006+1G>A Disrupts Iron Homeostasis and Drives Hereditary Hemochromatosis Pathogenesis
23 April 2026, Thursday	07:30 - 08:30	1456	ORAL PRESENTATION 08	anum LIAQUAT ALI	Determination of Ankyrin Repeats Domain (ANK) of RNASE L Gene in Hepatitis C Patients and its effects on Viral Load
23 April 2026, Thursday	07:30 - 08:30	1494	ORAL PRESENTATION 08	Zhenhua Zhang	Distinct Clinical Profile of Wilson Disease-Related Cirrhosis: Insights from a Propensity Score-Matched Multicenter Study
23 April 2026, Thursday	07:30 - 08:30	1672	ORAL PRESENTATION 08	Veronica Cumpata	Hepatic steatosis in Wilson disease: phenotype or metabolic comorbidity?
23 April 2026, Thursday	07:30 - 08:30	1897	ORAL PRESENTATION 08	Sujun Zheng	Genotype-Phenotype Correlation of ATP7B Mutations in Wilson Disease
23 April 2026, Thursday	07:30 - 08:30	1916	ORAL PRESENTATION 08	Jiaqi Li	Restoration of ATP7B Trafficking and Biliary Function in Wilson Disease Hepatocytes through CRISPR/Cas9-Mediated Gene Correction
23 April 2026, Thursday	07:30 - 08:30	1941	ORAL PRESENTATION 08	Anmol Anmol	Predictors and Immune Signatures of Baveno-VII–Aligned Recompensation in Pediatric Wilson Disease with Decompensated Cirrhosis
23 April 2026, Thursday	07:30 - 08:30	2134	ORAL PRESENTATION 08	Yue Han	Iron Metabolism Defects in Wilson Disease Suspects - A Real-World Two-Phase Molecular Epidemiology Study
23 April 2026, Thursday	07:30 - 08:30	2314	ORAL PRESENTATION 08	Sujun Zheng	Gilbert syndrome increases the risk of gallstone disease: a cross-sectional study based on health examination data from 338,372 adults
23 April 2026, Thursday	07:30 - 08:30	1101	ORAL PRESENTATION 09	seda zor	Association of Serum ALT Levels with Histological Activity and Fibrosis in Chronic Hepatitis B
23 April 2026, Thursday	07:30 - 08:30	1130	ORAL PRESENTATION 09	Mehmet Raşit Ayte	Effects of COVID-19 Vaccines on HBV Replication in Patients with Chronic Hepatitis B: A Comparative Analysis of mRNA and Inactivated Vaccines
23 April 2026, Thursday	07:30 - 08:30	1132	ORAL PRESENTATION 09	Zeynep Tekin Taş	POTENTIAL HERB-DRUG INTERACTIONS IN CHRONIC HEPATITIS B TREATMENT: A CASE SERIES
23 April 2026, Thursday	07:30 - 08:30	1153	ORAL PRESENTATION 09	David Hilmers	A Pilot Program of Community Volunteers to Improve Adherence to Hepatitis B Medications in Kiribati
23 April 2026, Thursday	07:30 - 08:30	1163	ORAL PRESENTATION 09	Zihao Fan	One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing
23 April 2026, Thursday	07:30 - 08:30	1168	ORAL PRESENTATION 09	Feng Ren	Peginterferon alpha-2b and nucleos(t)ide analogs combination therapy for chronic hepatitis B patients with high HBsAg level at the end of treatment (52 weeks) from ongoing CREATED Excellent Study
23 April 2026, Thursday	07:30 - 08:30	1173	ORAL PRESENTATION 09	Xiaoxin Wu	Unfolding Clinical Research Landscape on Bacterial Infections in Cirrhosis: Trends, Hotspots, and Analytical Insights
23 April 2026, Thursday	07:30 - 08:30	1204	ORAL PRESENTATION 09	Taiyu He	Sequential therapy with anti-PD-1 antibody and pegylated interferon-alpha promoted HBsAg reduction and enhanced T cell response in patients with chronic hepatitis B
23 April 2026, Thursday	07:30 - 08:30	1229	ORAL PRESENTATION 09	Jia Liu	PD-1 is required for the early expansion of HBV-specific CD8+ T cells and does not suppress their effector function during the acute phase of HBV infection
23 April 2026, Thursday	08:30 - 10:00	2580	ORAL PRESENTATION 10	Luyu Wang	PYGL: A novel non-invasive biomarker for diagnostic and prognostic of HEV-ALF patients
23 April 2026, Thursday	08:30 - 10:00	2590	ORAL PRESENTATION 10	Fadhyl Zuhry Lubis	The Predictive Value of Platelet-Derived Growth Factor for Evaluating Antiviral Therapy Response and Liver Stiffness Trajectory in Chronic Hepatitis B
23 April 2026, Thursday	08:30 - 10:00	2600	ORAL PRESENTATION 10	Muhsin Murat Muhip HARPUTLUOĞLU	Hepatitis B virus recurrence in liver transplant recipients receiving subcutaneous hepatitis B immunoglobulin
23 April 2026, Thursday	08:30 - 10:00	2601	ORAL PRESENTATION 10	İLYAS ETHEM ŞENOCAK	Diagnostic Accuracy and Long-Term Prognostic Value of FIB-4 Index and De Ritis Ratio in Chronic Hepatitis C Patients: A Comparative Kaplan-Meier Analysis with MELD 3.0
23 April 2026, Thursday	08:30 - 10:00	2608	ORAL PRESENTATION 10	Xiaoping Wu	Optimizing Pegylated Interferon Consolidation Therapy and Predicting Recurrence After Functional Cure in Chronic Hepatitis B: A Study Based on Updated Definitions
23 April 2026, Thursday	08:30 - 10:00	2630	ORAL PRESENTATION 10	Liu Yang	Single-cell transcriptomes reveal the immune characteristics of patients with chronic hepatitis B at different stages of disease progression
23 April 2026, Thursday	08:30 - 10:00	2663	ORAL PRESENTATION 10	Müge Toygar Deniz	High Prevalence of MASLD and MASH in Chronic Hepatitis B Patients: A Cross-Sectional Study
23 April 2026, Thursday	08:30 - 10:00	2711	ORAL PRESENTATION 10	Xiucheng Pan	Related Factors for Low-Level Viremia and the Comparative Efficacy of Management Strategies in Treatment-Naïve Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir Amibufenamide: A Real-World Study
23 April 2026, Thursday	08:30 - 10:00	2729	ORAL PRESENTATION 10	Yuhao Wang	Lactate triggers HBV-Specific CD8+ T cell exhaustion through mitophagy suppression mediated mitochondrial dysfunction
23 April 2026, Thursday	17:10 - 18:30	1232	ORAL PRESENTATION 11	EMİN EDİZ TÜTÜNCÜ	Preoperative Viral Hepatitis Screening: Evaluation of the Consultation Chain
23 April 2026, Thursday	17:10 - 18:30	1272	ORAL PRESENTATION 11	Qinzhi Deng	Comparing two intervention strategies to improve hepatitis B virus deoxyribonucleic acid testing rate among hepatitis B surface antigen-positive hospitalized patients
23 April 2026, Thursday	17:10 - 18:30	1277	ORAL PRESENTATION 11	Orçun Barkay	Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
23 April 2026, Thursday	17:10 - 18:30	1331	ORAL PRESENTATION 11	Emrullah ATAŞ	Evaluation of Hepatitis B Serology, Vaccination Rate, and Reactivation in Hepatitis C Patients Treated with Direct-Acting Antivirals
23 April 2026, Thursday	17:10 - 18:30	1344	ORAL PRESENTATION 11	SL Currie	A single VRON-0200 prime dose induced sustained and/or continued HBsAg declines up to one-year post dosing, and rapid HBsAg declines with addition of antiviral agents, in chronically HBV-infected patients
23 April 2026, Thursday	17:10 - 18:30	1353	ORAL PRESENTATION 11	Shan Ren	30% of Inactive HBsAg Carriers Achieved Clinical Cure at 48 Weeks with Pegylated Interferon Alpha-2b Therapy: A Multicenter Real-World Study (STARHB Project in China)- 3 years Data Update
23 April 2026, Thursday	17:10 - 18:30	1375	ORAL PRESENTATION 11	Yujuan Guan	Multidimensional analysis of diagnosis and treatment status of chronic hepatitis B
23 April 2026, Thursday	17:10 - 18:30	1399	ORAL PRESENTATION 11	Lin Tuo	Trajectory-Based Multidimensional Risk Scoring in a Single-Center Retrospective Cohort: Exploratory Development for Predicting Poor HBsAg Seroclearance Response in Chronic Hepatitis B Functional Cure
23 April 2026, Thursday	17:10 - 18:30	1410	ORAL PRESENTATION 11	Zhao Qian	Characterization of Serum Cytokine Profile and Its Early-Warning Value in Elderly Patients with Hepatitis E
23 April 2026, Thursday	18:30 - 20:00	1832	ORAL PRESENTATION 12	ADRIAN BUGAYONG	An Unexpected Turmoil: Hepatitis B Reactivation with Atypical Serology Following Neoadjuvant Capecitabine-Oxaliplatin in an Unsuspected Patient with Gastric Adenocarcinoma: A Multidisciplinary Management Complexity
23 April 2026, Thursday	18:30 - 20:00	1861	ORAL PRESENTATION 12	HATUN ÖZTÜRK ÇERİK	Test, Treat!: A Small Step For The World, A Big Step For Us; Hepatitis C Microelimination Efforts in a Small City in Türkiye
23 April 2026, Thursday	18:30 - 20:00	1886	ORAL PRESENTATION 12	Mengji Lu	The role of Alix and VPS4A in autophagy and endosomal pathways and their relation to HBV replication
23 April 2026, Thursday	18:30 - 20:00	1912	ORAL PRESENTATION 12	Xiao-hao Wang	Association Between Fatty Liver and Risk of Liver Failure in Patients with Acute Hepatitis B: A Retrospective Cohort Study
23 April 2026, Thursday	18:30 - 20:00	1920	ORAL PRESENTATION 12	ESMA ASLIHAN AYDEMİR	A New Noninvasive Marker Predicting Liver Fibrosis in Patients with Chronic Hepatitis B
23 April 2026, Thursday	18:30 - 20:00	1926	ORAL PRESENTATION 12	Sümeyra İstek	Hepatitis and HIV Seroprevalence in Individuals with Substance Use Disorders: A 25-Year Retrospective Analysis
23 April 2026, Thursday	18:30 - 20:00	1967	ORAL PRESENTATION 12	Lu Zhang	Hepatitis C Virus Micro‑elimination in the Hospital Setting: What Results Have We Achieved?
23 April 2026, Thursday	18:30 - 20:00	1984	ORAL PRESENTATION 12	Gule Cinar	Comparative Efficacy of Entecavir and Tenofovir Disoproxil Fumarate in Preventing HBV Reactivation in Patients Receiving Biologic Diasease-Modifying Antirheumatic Drugs
23 April 2026, Thursday	18:30 - 20:00	2002	ORAL PRESENTATION 12	Jacky Man Chun Chan	Acute Hepatitis B Infection Following Long‑Acting Injectable Antiretroviral Therapy Drug Switch in HIV
23 April 2026, Thursday	18:30 - 20:00	1010	ORAL PRESENTATION 13	Maria Diana Manalili	A Five-Year Retrospective Analysis of Hepatic Fibrosis and Steatosis Assessed by Transient Elastography in Patients Across the Glycemic Continuum
23 April 2026, Thursday	18:30 - 20:00	1042	ORAL PRESENTATION 13	Xinjie Li	Non-invasive detection of occult yet significant liver pathology in ALT-normal chronic hepatitis B: a multicenter study
23 April 2026, Thursday	18:30 - 20:00	1046	ORAL PRESENTATION 13	Thong Vo Duy	EVALUATING THE PROGNOSTIC VALUE OF THE MELD 3.0 SCORE IN PREDICTING MORTALITY IN CIRRHOSIS PATIENTS WITH ACUTE VARICEAL BLEEDING
23 April 2026, Thursday	18:30 - 20:00	1051	ORAL PRESENTATION 13	Ching Sheng Hsu	Physical performance is associated with severe liver fibrosis in patients with chronic liver disease
23 April 2026, Thursday	18:30 - 20:00	1147	ORAL PRESENTATION 13	Zeyi Zhang	Global, regional, and national burdens of cirrhosis in adolescents and young adults from 1990 to 2021
23 April 2026, Thursday	18:30 - 20:00	1190	ORAL PRESENTATION 13	Qiong Wu	Macrophage Nrf1-Foxo1-KLF6 Axis Drives Mitochondrial Dysfunction and Inflammatory Progression in Liver Fibrosis
23 April 2026, Thursday	18:30 - 20:00	1283	ORAL PRESENTATION 13	Chun-Ting Ho	Diagnostic Performance of Non-Invasive Serum Biomarkers for Fibrosis in Hepatocellular Carcinoma Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
23 April 2026, Thursday	18:30 - 20:00	1289	ORAL PRESENTATION 13	Rui Huang	Computed tomography-based hepatosplenic volumetry can predict all-cause and liver-related mortality in patients with cirrhosis
23 April 2026, Thursday	18:30 - 20:00	1312	ORAL PRESENTATION 13	Yi-Chun Wang	Multiparametric magnetic resonance imaging to risk-stratify patients with chronic liver disease: Descriptive results from the ELEGANCE study
23 April 2026, Thursday	18:30 - 20:00	1804	ORAL PRESENTATION 14	Wen Zhang	LOXL1 G153D Mutation Impairs Liver Fibrosis Regression by Enhancing Extracellular Matrix Stabilization
23 April 2026, Thursday	18:30 - 20:00	1805	ORAL PRESENTATION 14	Chenxue Hou	Clinical Validation and Diagnostic Value Assessment of Plasma GSTM3 as a Novel Biomarker for Liver Fibrosis
23 April 2026, Thursday	18:30 - 20:00	1816	ORAL PRESENTATION 14	Hong Li	The roles of THBS2-SPP1 axis in hepatic stellate cells activation and liver fibrogenesis
23 April 2026, Thursday	18:30 - 20:00	1818	ORAL PRESENTATION 14	Wenyue Wu	Selective Inhibition of Hepatic Stellate Cell-Derived Microfibril-associated glycoprotein 4 Attenuates Liver Fibrosis

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
23 April 2026, Thursday	18:30 - 20:00	1843	ORAL PRESENTATION 14	Yuanying Zhao	Gut-Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis
23 April 2026, Thursday	18:30 - 20:00	1889	ORAL PRESENTATION 14	Junhao Zha	Liver Fibrosis: Explainable Deep learning Network for Automated Staging by Using Equilibrium Enhanced Phase MR Images
23 April 2026, Thursday	18:30 - 20:00	1934	ORAL PRESENTATION 14	Hakan Demiröz	Comprehensive Evaluation of Demographic, Endoscopic, and Ultrasonographic Characteristics in First Episode Variceal Bleeding
23 April 2026, Thursday	18:30 - 20:00	2047	ORAL PRESENTATION 14	Zizhen Ye	Controlled expansion stent-grafts in TIPS: a real-world analysis of in vivo diameter change and early hepatic encephalopathy
23 April 2026, Thursday	18:30 - 20:00	2117	ORAL PRESENTATION 14	Tong Bu	Clinical Characteristics and Short-Term Outcomes of Patients with Cirrhosis and Subclinical Decompensation
23 April 2026, Thursday	18:30 - 20:00	1009	ORAL PRESENTATION 15	Jai Young Cho	Liver Resection versus Trans-arterial Chemoembolization for Huge Hepatocellular carcinoma (>10cm): A nationwide Propensity score adjusted analysis
23 April 2026, Thursday	18:30 - 20:00	1034	ORAL PRESENTATION 15	Yingcheng Wu	Charting immune and cancer metabolism co-evolution during metastasis
23 April 2026, Thursday	18:30 - 20:00	1035	ORAL PRESENTATION 15	Na Fu	Targeting PAK1 on tumour-associated macrophages enhances the efficacy of immunotherapy in hepatocellular carcinoma
23 April 2026, Thursday	18:30 - 20:00	1481	ORAL PRESENTATION 15	Xin Wen	Development and validation of brain age clock from psychometric hepatic encephalopathy score for early detection of hepatic encephalopathy
23 April 2026, Thursday	18:30 - 20:00	1940	ORAL PRESENTATION 15	MOHD. IBRAHIM KHAN	Dual SGLT2-DPP-4 Inhibition Synergistically Restores Hepatopancreatic Integrity in Experimental Diabetes
23 April 2026, Thursday	18:30 - 20:00	2041	ORAL PRESENTATION 15	Ferdinand Anzo	A Rare Presentation of Salmonella enteritidis Bacteremia With Coronary Mycotic Aneurysm and Non-Cirrhotic Portal Hypertension
23 April 2026, Thursday	18:30 - 20:00	2364	ORAL PRESENTATION 15	Oğuzhan Acet	Hepatic Involvement and Drug-Induced Liver Injury in Brucellosis
23 April 2026, Thursday	18:30 - 20:00	2378	ORAL PRESENTATION 15	Tong Chen	Metabolic Dysfunction–Associated Liver Disease and Lung Injury: A Decade of Progress Toward Mechanistic Integration and Translational Insight
23 April 2026, Thursday	18:30 - 20:00	2774	ORAL PRESENTATION 15	Wanyue Cao	Adipose-derived FABP5 drives myeloid bias in hematopoietic stem cells and promotes tumor progression.
23 April 2026, Thursday	18:30 - 20:00	1039	ORAL PRESENTATION 16	Deyuan Zhong Zhong	Preoperative TACE with PD-1 Inhibitors and TKIs in Beyond “Up-to-Seven” Hepatocellular Carcinoma: A Propensity Score Matched Analysis
23 April 2026, Thursday	18:30 - 20:00	1065	ORAL PRESENTATION 16	Xiaoyan Chi	Epigenetic regulation and functional mechanisms of the ZSCAN23 gene in liver cancer
23 April 2026, Thursday	18:30 - 20:00	1096	ORAL PRESENTATION 16	Yuxin Liang	Triplet Therapy with Envafolimab, Lenvatinib, and TACE Enables Curative Conversion and Pathological Response in Unresectable HCC: A Single-Arm Phase II study
23 April 2026, Thursday	18:30 - 20:00	1116	ORAL PRESENTATION 16	Muhammad Rezki Rasyak	Racial Disparities in Hepatocellular Carcinoma: A TCGA-Based Gene Expression Study of Caucasian and Asian Populations
23 April 2026, Thursday	18:30 - 20:00	1118	ORAL PRESENTATION 16	Rui Zhao	Targeting Premalignant Liver Lesions with Dietary Bioactive Compounds: From Multi-Targeted Mechanisms to Precision Prevention
23 April 2026, Thursday	18:30 - 20:00	1141	ORAL PRESENTATION 16	Xianglong Chen	Sequential met inhibition from crizotinib to capmatinib in a patient with advanced met-amplified intrahepatic cholangiocarcinoma:a case report
23 April 2026, Thursday	18:30 - 20:00	1149	ORAL PRESENTATION 16	Yao Yang	Dead-box helicase1 promote cancer stemness of hepatocellular carcinoma by enhancing FSCN1 mRNA translation
23 April 2026, Thursday	18:30 - 20:00	1245	ORAL PRESENTATION 16	Chien-Wei Su	Combined Application of Serum Alpha-Fetoprotein and PIVKA-II Levels for Prognostic Stratification in Patients With Hepatocellular Carcinoma
23 April 2026, Thursday	18:30 - 20:00	2359	ORAL PRESENTATION 17	Kyoko Oura	Stage-Specific Survival in Hepatocellular Carcinoma: A Multiregional Analysis Across Japan vs Non-Japan Cohorts in the Asia-Pacific Region
23 April 2026, Thursday	18:30 - 20:00	2418	ORAL PRESENTATION 17	Maria Fleurdeliz Goco-Siatan	AFP trajectories in HCC after ablation treatment: a 15 year retrospective study
23 April 2026, Thursday	18:30 - 20:00	2454	ORAL PRESENTATION 17	ONUR DURNA	Anticancer Effects of Bromelain on HUH7 Hepatocellular Carcinoma Cells through Modulation of the EGFR/PI3K Pathway
23 April 2026, Thursday	18:30 - 20:00	2460	ORAL PRESENTATION 17	Akshyata Osti	Comparative Efficacy of Lenvatinib Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Meta-Analysis of Meta-Analyses
23 April 2026, Thursday	18:30 - 20:00	2491	ORAL PRESENTATION 17	Hasmik Ghazinyan	Hepatocellular Carcinoma in Armenia: Liquid Biopsies and Primary Assessment of Molecular Alterations Prevalence
23 April 2026, Thursday	18:30 - 20:00	2572	ORAL PRESENTATION 17	Fanping Meng	Short-Course Adjuvant Tislelizumab plus Tyrosine Kinase Inhibitor Following Curative Ablation for Early-Stage Hepatocellular Carcinoma: A Prospective Cohort Study
23 April 2026, Thursday	18:30 - 20:00	2579	ORAL PRESENTATION 17	Liren Zhang	YTHDF1high cancer-associated fibroblasts-derived kynurenine promotes tumor progression by supplying an immunosuppressive niche
23 April 2026, Thursday	18:30 - 20:00	2627	ORAL PRESENTATION 17	Wang Hao	ZIP1⁺ CAFs Shape the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression
23 April 2026, Thursday	18:30 - 20:00	2644	ORAL PRESENTATION 17	Liu Jiangxi	FKBP10⁺ CAFs Shape the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression
23 April 2026, Thursday	18:30 - 20:00	1158	ORAL PRESENTATION 18	Mohamad Jamalinia	Donor Isolated Hyperbilirubinemia and Post-Liver Transplant Survival: A Propensity-Matched Analysis
23 April 2026, Thursday	18:30 - 20:00	1162	ORAL PRESENTATION 18	Xianzhang Luo	Study on the Mechanism of Samhd1 Mediated NEMO Polyubiquitination in Liver Ischemia-Reperfusion Injury
23 April 2026, Thursday	18:30 - 20:00	1164	ORAL PRESENTATION 18	Zhenghua Luo	Study on the Mechanism of TRIM55 Mediating K63 Polyubiquitination of Bcl10 Protein to Aggravate Liver Ischemia-Reperfusion Injury
23 April 2026, Thursday	18:30 - 20:00	1167	ORAL PRESENTATION 18	Penghong Song	SERPINE2 mitigates hepatic ischemia–reperfusion injury via a SUMO–ubiquitin rheostat
23 April 2026, Thursday	18:30 - 20:00	1174	ORAL PRESENTATION 18	Qingyun Xie	A Ten-Year Comparative Analysis of Open vs. Laparoscopic Anatomical Hepatectomy for Right-Sided Complex Hepatocellular Carcinoma: A Large-Sample, Nationwide Multicenter Real-World Study
23 April 2026, Thursday	18:30 - 20:00	1237	ORAL PRESENTATION 18	‪Ekram Hasanin‬‏	Novel Trends in Liver Transplantation for MASLD and ALD: Emerging Epidemiology, Allocation & Post-Transplant Challenges
23 April 2026, Thursday	18:30 - 20:00	1243	ORAL PRESENTATION 18	Seyed Mohammad Amin Dashti	Liver Transplantation Outcomes in Primary Sclerosing Cholangitis Patients With and Without Ulcerative Colitis: A Comparative Analysis
23 April 2026, Thursday	18:30 - 20:00	1598	ORAL PRESENTATION 18	Zehra İkbal Karabal	Pneumonia incidence and pathogen spectrum in liver transplant recipients: a decade-long retrospective analysis comparing pre-coronavirus disease 2019 and pandemic-era temporal patterns and risk factors
23 April 2026, Thursday	18:30 - 20:00	1846	ORAL PRESENTATION 18	Zulihumaer Aizimuaji	Patient-Derived Liver Organoids as a Translational Platform to Validate Targeted Nanoparticles for Image-Guided Liver Cancer Surgery
23 April 2026, Thursday	18:30 - 20:00	1176	ORAL PRESENTATION 19	Guixin Li	METTL16 drives MAFLD progression by regulating lipid synthesis and immune responses
23 April 2026, Thursday	18:30 - 20:00	1209	ORAL PRESENTATION 19	Feixiang Xiong	Therapeutic Effects of Qinggan Huatan Huoxue Prescription on Metabolic Dysfunction-Associated Steatohepatitis via Modulation of the CYP4a32–PPARγ–CD36 Signaling Axis
23 April 2026, Thursday	18:30 - 20:00	1226	ORAL PRESENTATION 19	Carolyn Wallace	Metabolic dysfunction-associated steatotic liver disease by fibrosis stage in China and Japan: a 20-year model
23 April 2026, Thursday	18:30 - 20:00	1250	ORAL PRESENTATION 19	Jie Liu	Identifying MASLD Patients with MASH or Significant Fibrosis : The Role of Lower ALT Thresholds
23 April 2026, Thursday	18:30 - 20:00	1265	ORAL PRESENTATION 19	Chen-Te Huang	Risk factors for advanced liver fibrosis in psoriasis patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
23 April 2026, Thursday	18:30 - 20:00	1281	ORAL PRESENTATION 19	Katelyn Chiu	Short-Term Gains, Long-Term Challenges: A Pilot Randomized Controlled Trial for Time-Restricted Feeding Versus Caloric Restriction in Significant MASLD
23 April 2026, Thursday	18:30 - 20:00	1284	ORAL PRESENTATION 19	Hirokazu Takahashi	Antifibrotic Efficacy and Renal Safety of Pemafibrate in MASLD: A Multicenter Randomized Controlled Study
23 April 2026, Thursday	18:30 - 20:00	1286	ORAL PRESENTATION 19	Akio Moriya	Clinical characteristics of diabetic patients with limited improvement in elevated ALT following tirzepatide initiation
23 April 2026, Thursday	18:30 - 20:00	1334	ORAL PRESENTATION 19	Katelyn Chiu	Time-Restricted Feeding Improves Hepatic Fibrosis in Advanced MASLD: Preliminary Results from a Randomised Controlled Trial
24 April 2026, Friday	07:30 - 09:00	1422	ORAL PRESENTATION 20	Li Bai	Unveiling the pathogenesis and early warning biomarkers of acute liver failure associated with disulfidptosis through bioinformatics analysis and experimental validation
24 April 2026, Friday	07:30 - 09:00	1426	ORAL PRESENTATION 20	Xiao Che	Double plasma molecular adsorption system improves 90-day survival in patients with acute-on-chronic liver failure
24 April 2026, Friday	07:30 - 09:00	1471	ORAL PRESENTATION 20	Neha Sharma	Biomolecular Mapping of Circulating Extracellular Vesicles to Develop AI Driven Prognostic Panels for Stratifying Acute Liver Failure Patients at Risk of Early Mortality
24 April 2026, Friday	07:30 - 09:00	1497	ORAL PRESENTATION 20	Liang Peng	A Phase I Clinical Trial Evaluating the Safety and Efficacy of the QH-1A Combination Bio-artificial Liver Support System Incorporating Ex-vivo Mesenchymal Stem Cells for the Treatment of ACLF patients
24 April 2026, Friday	07:30 - 09:00	1834	ORAL PRESENTATION 20	Rungfah Saehan	The national burden of acute liver failure from 2019 to 2022: A Thailand nationwide population-based cross-sectional time series study
24 April 2026, Friday	07:30 - 09:00	1857	ORAL PRESENTATION 20	Alfiyyah Rizqy	Therapeutic Role of N-Acetylcysteine in Acute Liver Failure Secondary to Anti-Tuberculosis Drug-Induced Liver Injury: Insights From Indonesia
24 April 2026, Friday	07:30 - 09:00	1895	ORAL PRESENTATION 20	Yufei BI	Add on traditional Chinese medicine for hospitalized acute on chronic liver disease
24 April 2026, Friday	07:30 - 09:00	1943	ORAL PRESENTATION 20	Seydanur Avci	Investigation of the Therapeutic Effects of β3-Adrenergic Stimulation on Paracetamol-Induced Acute Liver Damage
24 April 2026, Friday	07:30 - 09:00	1950	ORAL PRESENTATION 20	Chen Zhou	Decellularized Liver Matrix from Healthy versus Acute Liver Failure Livers Possesses Distinct Structural and Functional Properties
24 April 2026, Friday	07:30 - 09:00	1486	ORAL PRESENTATION 21	Yanpei Mai	Serum bile acids profile analysis predicts severity and progression of liver disease
24 April 2026, Friday	07:30 - 09:00	1573	ORAL PRESENTATION 21	A B M Shakil Gani	Comparison of ALBI, PALBI, MELD, and Child–Pugh Scores in Chronic Liver Disease: Evidence from Bangladesh

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
24 April 2026, Friday	07:30 - 09:00	1649	ORAL PRESENTATION 21	ZANNATUL HABIBA	Platelet-Albumin-Bilirubin (PALBI) Score: A non-invasive Predictor of Esophageal Varices in Patients with Liver Cirrhosis Compared to Child-Turcotte-Pugh (CTP) Score
24 April 2026, Friday	07:30 - 09:00	2320	ORAL PRESENTATION 21	Jaswinder Maras	Liver meta-proteome and kinome reveal Pseudomonas aeruginosa –pPKCη axis as a driver of steroid resistance in severe alcohol related hepatitis
24 April 2026, Friday	07:30 - 09:00	2375	ORAL PRESENTATION 21	Zhiying He	Achieving Recompensation with Low-dose Diuretics in HBV-related Cirrhosis: An Expanded Baveno VII Strategy Yields Similar Long-Term Prognosis in A Multicenter Cohort Study
24 April 2026, Friday	07:30 - 09:00	2422	ORAL PRESENTATION 21	Yrah Damiene Fernandez	Diagnostic Accuracy of Portal System Duplex Sonography Findings Among Filipinos with and Without Liver Cirrhosis; The DupLiCs Study
24 April 2026, Friday	07:30 - 09:00	2438	ORAL PRESENTATION 21	ANKUR JINDAL	Long-term Serial Liver Stiffness Monitoring, Histological Fibrosis, and HVPG as Determinants of Disease Progression and Decompensation in MASLD
24 April 2026, Friday	07:30 - 09:00	2441	ORAL PRESENTATION 21	Nipun Verma	MACHINE-LEARNING MODELS IMPROVES MORTALITY AND ANTIMICROBIAL RESISTANCE PREDICTION IN CULTURE-PROVEN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOSIS: A MULTICENTER COHORT STUDY
24 April 2026, Friday	07:30 - 09:00	2484	ORAL PRESENTATION 21	Yanna Liu	CT-based Vasomics model for noninvasive diagnosis of Porto-sinusoidal vascular disease in patients with portal hypertension
24 April 2026, Friday	07:30 - 09:00	1037	ORAL PRESENTATION 22	Mengyi Shen	Engineered Vesicle-Mediated Metabolic Regulation and Immune Targeting for the Treatment of Autoimmune Hepatitis
24 April 2026, Friday	07:30 - 09:00	1233	ORAL PRESENTATION 22	Li Zhang	Predictors of response to ursodeoxycholic acid treatment and non-invasive identification of autoimmune hepatitis tendencies in primary biliary cholangitis
24 April 2026, Friday	07:30 - 09:00	2353	ORAL PRESENTATION 22	Erdi Şeker	Analysis of Aggressive Phenotypes in Hepatocellular Carcinoma Using Transcriptomic Data: A Machine Learning Framework for Biological Signature Discovery
24 April 2026, Friday	07:30 - 09:00	2496	ORAL PRESENTATION 22	Arjun Maria	Development and validation of an artificial intelligence driven convolutional neural network for automated stool colour classification to facilitate early diagnosis of biliary atresia
24 April 2026, Friday	07:30 - 09:00	2583	ORAL PRESENTATION 22	Zhuoru Jiang	Head-to-Head Comparison Between MRI and A Novel Portable VCTE Device (Liverscan): A Pilot Study
24 April 2026, Friday	07:30 - 09:00	2639	ORAL PRESENTATION 22	Harsh Vardhan Tevethia Tevethia	Machine learning(ML) based models predict beta-blocker response using non-invasive tests(NITs) in patients with acute variceal bleed -BE-RESPONSE STUDY
24 April 2026, Friday	07:30 - 09:00	2851	ORAL PRESENTATION 22	Sümeyye AĞIR	From Synthetic to Clinical: The Effect of Domain Shift on Decision Support Systems
24 April 2026, Friday	07:30 - 09:00	2860	ORAL PRESENTATION 22	YAO YUNLONG	Advances in Artificial Intelligence for Liver Disease Research: Algorithmic Applications and Technical Challenges
24 April 2026, Friday	07:30 - 09:00	2881	ORAL PRESENTATION 22	Bo WANG	Impact of an AI-Supported Triage System on the Diagnostic Workflow of Focal Pancreatic Lesions: A Real-World Clinical Utility Analysis
24 April 2026, Friday	07:30 - 09:00	1103	ORAL PRESENTATION 23	Yusuf Bunyamin Ketenci	Unusual Partners in Anemia: Zieve’s Syndrome and Beta-Thalassemia Trait in a Single Patient: A case report and literature review
24 April 2026, Friday	07:30 - 09:00	1117	ORAL PRESENTATION 23	Yun-Chieh Su	ADH1B rs6850217 as a Novel Genetic Determinant of Hepatocellular Carcinoma Risk in Chronic Hepatitis B
24 April 2026, Friday	07:30 - 09:00	1215	ORAL PRESENTATION 23	GAURAV TRIPATHI	Oxysterol-Binding Protein-Related Protein 2 Drives Sterol Accumulation and Neutrophil Dysfunction in Sepsis Associated with Alcoholic Cirrhosis
24 April 2026, Friday	07:30 - 09:00	1310	ORAL PRESENTATION 23	Xianwei Liu	Creb1-regulated slc39a1 attenuates alcoholic liver disease by orchestrating autophagy and mitophagy
24 April 2026, Friday	07:30 - 09:00	1350	ORAL PRESENTATION 23	Jiarui Zheng	Metabolic Syndrome is Independently Associated with 1-Year Readmission of Patients with Alcohol-Associated Cirrhosis
24 April 2026, Friday	07:30 - 09:00	2443	ORAL PRESENTATION 23	Aditya Soni	Histological severity is not associated with clinical presentation or outcome in children with autoimmune hepatitis
24 April 2026, Friday	07:30 - 09:00	2681	ORAL PRESENTATION 23	Lili zhao	Characteristics of Autoimmune Hepatitis in elderly patients
24 April 2026, Friday	07:30 - 09:00	2700	ORAL PRESENTATION 23	Ayse Sena Oguz	Does Primary Biliary Cholangitis and Autoimmune Hepatitis Increase the Risk of Precancerous Colon Polyps?
24 April 2026, Friday	07:30 - 09:00	2760	ORAL PRESENTATION 23	Astrid Amador	Real-world Biochemical Responses to First-line Azathioprine versus Mycophenolate and Upon Switching from Azathioprine to Mycophenolate in Autoimmune Hepatitis Patients
24 April 2026, Friday	07:30 - 09:00	1903	ORAL PRESENTATION 24	Rafael Emmanuel Mendoza	Performance of FIB-4 and MAFLD Fibrosis Score vs. Transient Elastography in a Filipino Cohort
24 April 2026, Friday	07:30 - 09:00	1968	ORAL PRESENTATION 24	Elif Cadirci	Investigation of the Effects of Vasopressin V2 Receptor Inhibition on Aquaporin Expression and Liver Functions in Sepsis-Induced Hepatic Injury
24 April 2026, Friday	07:30 - 09:00	2068	ORAL PRESENTATION 24	Ruixuan Hong	The impact of implementing the expanded antiviral therapy eligibility for HBsAg-positive pregnant women in China: a modelling study
24 April 2026, Friday	07:30 - 09:00	2132	ORAL PRESENTATION 24	Ajeet Singh Bhadoria	Leveraging Decentralization, Integration, and Task-Shifting to achieve Micro-elimination of Hepatitis C among prisoners in Northern India
24 April 2026, Friday	07:30 - 09:00	2296	ORAL PRESENTATION 24	Mohamed Abd Allah	From Campaign to Validation: Operationalizing Egypt’s National Sustainability Plan for Viral Hepatitis Elimination (2025–2030)
24 April 2026, Friday	07:30 - 09:00	2318	ORAL PRESENTATION 24	Manisha Yadav	Gut Microbiota Transfer and Integrated Omics Identify Streptococcal Collagen-Like (Scl1) Protein as a key fibrogenic driver in Alcohol associated liver disease.
24 April 2026, Friday	07:30 - 09:00	2350	ORAL PRESENTATION 24	Shiwen Ma	Generation of Macro-Scale Engineered Biliary Trees with P-gp Efflux Function and Enhanced Injury Resistance
24 April 2026, Friday	07:30 - 09:00	2360	ORAL PRESENTATION 24	Neslihan Başgöz Karaguş	Amlodipine activates an adaptive endoplasmic reticulum stress response in Huh-7 hepatocellular carcinoma cells
24 April 2026, Friday	07:30 - 09:00	2361	ORAL PRESENTATION 24	Ahmet Ozan Kaleci	L-canavanine selectively inhibits hepatocellular carcinoma cell proliferation and induces apoptosis in vitro
24 April 2026, Friday	07:30 - 09:00	1824	ORAL PRESENTATION 25	NIVEDITA NIVEDITA	Utility of EUS-guided Liver Biopsy in Liver Disease.
24 April 2026, Friday	07:30 - 09:00	1923	ORAL PRESENTATION 25	Wenjing Wang	Women's Perspective on Non-Antibiotic Interventions for rUTI Prevention: Meta-Analysis of Efficacy, Safety, and Clinical Implications
24 April 2026, Friday	07:30 - 09:00	2244	ORAL PRESENTATION 25	Rajit Gilhotra	Early Experience with Endoscopic Ultrasound–Guided Gastric Variceal Obliteration at an Australian Quaternary Referral Centre
24 April 2026, Friday	07:30 - 09:00	2427	ORAL PRESENTATION 25	Arka De	Endoscopic Ultrasound–Guided Portosystemic Pressure Gradient Measurement To Determine Candidacy For Simultaneous Liver–Kidney Transplantation Vs Renal Transplant Alone In End-Stage Renal Disease Patients With Compensated Advanced Chronic Liver Disease or Cirrhosis
24 April 2026, Friday	07:30 - 09:00	2432	ORAL PRESENTATION 25	Arpit Shastri	Endoscopic Ultrasound Guided Ablative Therapies For Hepatocellular Carcinoma
24 April 2026, Friday	07:30 - 09:00	2483	ORAL PRESENTATION 25	Yanan Sun	Endoscopic treatment for esophagogastric variceal bleeding in acute-on-chronic liver failure patients
24 April 2026, Friday	07:30 - 09:00	2519	ORAL PRESENTATION 25	Sercan Kiremitci	The long term results of EUS guided coil application for fundal varices
24 April 2026, Friday	07:30 - 09:00	2553	ORAL PRESENTATION 25	Hakan Şentürk	EUS guided liver biopsy for diffuse liver disases is an emerging alternative to percutaneous liver biopsy
24 April 2026, Friday	07:30 - 09:00	1007	ORAL PRESENTATION 26	Atteyat A. Semeya	Direct-Acting Antiviral Therapy Reduces Variceal Rebleeding and Improves Liver Function in HCV-Related Cirrhosis: A Multicenter Retrospective Study in Egypt
24 April 2026, Friday	07:30 - 09:00	1011	ORAL PRESENTATION 26	Arailym Maikenova	Predictors of non-response to antiviral therapy for hepatitis C in Almaty, the largest city of Kazakhstan
24 April 2026, Friday	07:30 - 09:00	1013	ORAL PRESENTATION 26	Yuan Liu	Non-invasive prediction of hepatic inflammation grade in chronic hepatitis B patients based on multiple parameters non-enhancement MRI combined with clinical characteristics
24 April 2026, Friday	07:30 - 09:00	1029	ORAL PRESENTATION 26	Changle Wu	Global burden of hepatitis A virus 1990–2023: results from the Global Burden of Disease Study 2023
24 April 2026, Friday	07:30 - 09:00	1045	ORAL PRESENTATION 26	Tugba Sari	The Denizli Model: A Leading Strategy in the War on Hepatitis C
24 April 2026, Friday	07:30 - 09:00	1076	ORAL PRESENTATION 26	I Wayan Rendi Awendika	Optimizing Risk Stratification of Esophageal Varices for Endoscopic Surveillance: Diagnostic Value of APRI, FIB-4, King, and Bonacini Scores in Hepatitis-Related Liver Disease
24 April 2026, Friday	07:30 - 09:00	1098	ORAL PRESENTATION 26	Grace Wong	Disease burden of chronic hepatitis D virus (HDV) infection among people living with chronic hepatitis B virus (HBV) infection in a low-endemic city
24 April 2026, Friday	07:30 - 09:00	1423	ORAL PRESENTATION 26	Myriam Drysdale	Characterisation of people living with chronic hepatitis B virus infection in China and stratification by HBsAg levels
24 April 2026, Friday	07:30 - 09:00	1436	ORAL PRESENTATION 26	Yi Wang	HBV Inhibits Stress Granule Formation by Hijacking SG Core Proteins into the Nucleocapsids
24 April 2026, Friday	07:30 - 09:00	1195	ORAL PRESENTATION 27	Jia Liu Liu	MMP-9 Suppresses the Anti-HBsAg B Cell Response During Chronic HBV Infection
24 April 2026, Friday	07:30 - 09:00	1305	ORAL PRESENTATION 27	Yansheng Liu	Fenofibrate and ursodeoxycholic acid in treatment-naïve primary biliary cholangitis: a pilot randomized trial with integrated multi-omics analysis
24 April 2026, Friday	07:30 - 09:00	1542	ORAL PRESENTATION 27	Qi Wang	Mechanistic Insights into the Protective Effects of Faecalibacterium prausnitzii and Its Metabolite Short Chain Fatty Acids on Biliary Injury in Primary Biliary Cholangitis
24 April 2026, Friday	07:30 - 09:00	1798	ORAL PRESENTATION 27	Atsushi Tanaka	East Asian subgroup analysis of the global Phase 3 GLISTEN study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC)
24 April 2026, Friday	07:30 - 09:00	1938	ORAL PRESENTATION 27	ikram aluahabi	Prediction of Esophageal Varices in Primary Biliary Cholangitis: What Is the Role of Non-Invasive Tests?
24 April 2026, Friday	07:30 - 09:00	2793	ORAL PRESENTATION 27	Yanchen Ma	4-1BB Costimulation Restore Tfh1 Function to Augment HBV-Specific Humoral Immunity in Chronic Infection
24 April 2026, Friday	07:30 - 09:00	2796	ORAL PRESENTATION 27	Shihong Zhong	Interferon-α programs HBsAg-specific humoral immunity through the monocyte-IL6-Tfh cell axis to facilitate functional cure of hepatitis B
24 April 2026, Friday	07:30 - 09:00	2818	ORAL PRESENTATION 27	Emiliia Krasavina	Updated results of the observational study to assess virological effectiveness, safety, and tolerability of NVR/RTV+SOF combination in HCV infected people living with HIV
24 April 2026, Friday	07:30 - 09:00	2888	ORAL PRESENTATION 27	Munira Jahan Jahan	Evaluation of selected Plasma Long Non-Coding RNAs as predictive Biomarkers in HBV-Related Hepatocellular Carcinoma

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
24 April 2026, Friday	07:30 - 09:00	1328	ORAL PRESENTATION 28	Hiba Al Lawati	CRISPR Prime Targeting of Interleukin 1 Receptor Type 1 (Il1r1) in Stellate Cells Identifies a Pathogenic Inflammation-to-Fibrosis Axis in the Liver
24 April 2026, Friday	07:30 - 09:00	1361	ORAL PRESENTATION 28	Swarup Sasidharan	L-Taurine for Fatigue in Decompensated Cirrhosis: A Randomized Controlled Trial
24 April 2026, Friday	07:30 - 09:00	1377	ORAL PRESENTATION 28	Yanhua Chen	Computed tomography-based sarcopenic obesity can predict cardiovascular and cerebrovascular mortality in patients with cirrhosis
24 April 2026, Friday	07:30 - 09:00	1389	ORAL PRESENTATION 28	M Golam Azam Azam MG	Variability of Presentation of Cholelithiasis in Relation to Etiology and Stages of Cirrhosis of Liver in a Tertiary Care Hospital in Dhaka City
24 April 2026, Friday	07:30 - 09:00	1408	ORAL PRESENTATION 28	Yuwei Wang	Predicting Recompensation and Exploring the Prognostic Benefit of its Durability in patients with HBV-related decompensated cirrhosis
24 April 2026, Friday	07:30 - 09:00	1419	ORAL PRESENTATION 28	Zongyi Liu	Evodiamine alleviates liver fibrosis by targeting the ANXA2/PI3K/AKT/CCND1 axis in hepatic stellate cells
24 April 2026, Friday	07:30 - 09:00	1507	ORAL PRESENTATION 28	Maria Nadinskaia	Hyperammonemia in pre-hepatic and intrahepatic portal hypertension: comparable levels, different clinical outcomes
24 April 2026, Friday	07:30 - 09:00	1551	ORAL PRESENTATION 28	Mohamed Abdel-Samiee	Non Invasive Detection of Esophageal Varices in Compensated Cirrhotic Patients
24 April 2026, Friday	07:30 - 09:00	1568	ORAL PRESENTATION 28	Bingqing Yang	Role of CD146-High Endothelial Cells in Vascular Remodeling and Fibrosis Progression in Cirrhotic Liver: A Single-Cell Transcriptomic Study
24 April 2026, Friday	10:50 - 12:10	1527	ORAL PRESENTATION 29	Ruochan Chen	Development and Validation of an Early Diagnostic Model to Distinguish Bacterial Infection in Patients with Acute-on-Chronic Liver Disease (AoCLD) and Systemic Inflammatory Response Syndrome (SIRS)
24 April 2026, Friday	10:50 - 12:10	1531	ORAL PRESENTATION 29	Demin Yu	Dynamic changes in gut microbiota associated with HBsAg decline in chronic hepatitis B patients undergoing IFN treatment
24 April 2026, Friday	10:50 - 12:10	1533	ORAL PRESENTATION 29	Qiao Tang	Sex differences in cirrhosis among untreated chronic hepatitis B: a 10-year longitudinal cohort study from China
24 April 2026, Friday	10:50 - 12:10	1555	ORAL PRESENTATION 29	Elif Nur Özbay Haliloğlu	Concordance Between Ultrasound Steatosis Grading and Elastography-CAP Classification: A Case Series of Chronic HBV Patients on TAF Therapy
24 April 2026, Friday	10:50 - 12:10	1560	ORAL PRESENTATION 29	Dr Arifa Tasnim	Correlation between transient elastography and liver biopsy in CHB patients with elevated HBV DNA with normal ALT
24 April 2026, Friday	10:50 - 12:10	1565	ORAL PRESENTATION 29	Qiuju Sheng	The Efficacy and Safety of Pegylated Interferon Alpha Treatment in Patients with HBV Related Cirrhosis and HCC after Radical Surgery (1 Year Data from the TERMINATOR Project)
24 April 2026, Friday	10:50 - 12:10	1567	ORAL PRESENTATION 29	Conglin Zhao	Multi-omics Analysis of Bile Acid Dysregulation in Hepatitis E virus Infection
24 April 2026, Friday	10:50 - 12:10	1589	ORAL PRESENTATION 29	Yanjie Lin	Intermittent therapy restores anti-HBV efficacy of IFN by reducing elevated dysfunctional HLA-DR+CD38hiCD8+ T lymphocytes
24 April 2026, Friday	10:50 - 12:10	1602	ORAL PRESENTATION 29	Xuejie Zhang	The Association Analysis of Metabolic Comorbidities and the 10-Year Prognosis of Hepatic Events in Chronic Hepatitis B Patients
24 April 2026, Friday	10:50 - 12:10	2137	ORAL PRESENTATION 30	Dr. Aftab Abbasi	Protective and Therapeutic Roles of Vitamin D in Reducing Chlorpyrifos Induced Liver Fibrosis Through Modulation of Fibrotic Pathways
24 April 2026, Friday	10:50 - 12:10	2188	ORAL PRESENTATION 30	Gamal Shiha	Personalised Risk-Based HCC Surveillance in HCV-Related Advanced Fibrosis/Cirrhosis After SVR: Real-World Evidence of Cost Effectiveness.
24 April 2026, Friday	10:50 - 12:10	2201	ORAL PRESENTATION 30	Murat Taner GÜLŞEN	Prospective Evaluation of Factors Affecting Measurement Quality in Liver Elastography
24 April 2026, Friday	10:50 - 12:10	2226	ORAL PRESENTATION 30	Javaria Younas Muhammad Younas	Impact of Diabetes on Fibrosis Progression in NAFLD: A Systematic Review and Meta-analysis
24 April 2026, Friday	10:50 - 12:10	2302	ORAL PRESENTATION 30	Shuntaro Obi	Stiffness Regression Fundamentally Alters Mortality Patterns and Improves Survival in Advanced Fibrosis After SVR: A Cause-Specific Outcome Analysis
24 April 2026, Friday	10:50 - 12:10	2309	ORAL PRESENTATION 30	Thi Thanh Thuy Le	Zonal Restoration and Inter-Cellular Signaling in Fibrosis Regression: Single-Cell Transcriptomics Decodes the Pericentral Hepatocyte-HSC Axis
24 April 2026, Friday	10:50 - 12:10	2311	ORAL PRESENTATION 30	Xuzhen Yan	LOXL1 Regulates Lipid Metabolism to Promote Hepatic Stellate Cell Activation via Ubiquitin-Mediated FASN Degradation
24 April 2026, Friday	10:50 - 12:10	2349	ORAL PRESENTATION 30	Xuemei WANG	Study on the Anti-Liver Cirrhosis of Luteolin: Targeting the PPARα Axis to Regulate Macrophage Fatty Acid Metabolic Reprogramming
24 April 2026, Friday	10:50 - 12:10	2369	ORAL PRESENTATION 30	Fei Wang	AGIUS Score Predicts Re-bleeding Risk after Endoscopic Variceal Ligation in Cirrhotic Patients Introduction
24 April 2026, Friday	10:50 - 12:10	1280	ORAL PRESENTATION 31	Jia-Yong Su	Tislelizumab plus lenvatinib versus tislelizumab monotherapy as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence : a prospective, multicenter cohort study
24 April 2026, Friday	10:50 - 12:10	1308	ORAL PRESENTATION 31	Wenying Qiao	KDM5A-Driven Epigenetic Reprogramming of IL1B⁺ CD14⁺ Monocytes Mediates Resistance to Anti–PD-1 Therapy in Advanced Hepatocellular Carcinoma by Suppressing T Cell-Mediated Antitumor Immunity
24 April 2026, Friday	10:50 - 12:10	1326	ORAL PRESENTATION 31	Irene Oi-Lin Ng	Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma and mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression
24 April 2026, Friday	10:50 - 12:10	1349	ORAL PRESENTATION 31	Van Trung Huynh	Enhanced detection of hepatocellular carcinoma using combined biomarker panels including alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxyprothrombin and the galad score
24 April 2026, Friday	10:50 - 12:10	1393	ORAL PRESENTATION 31	Da-Long Yang	Optimal timing of hepatectomy after conversion therapy and stratification by risk of recurrence in patients with hepatocellular carcinoma: a multicenter retrospective investigation (GUIDANCE005)
24 April 2026, Friday	10:50 - 12:10	1396	ORAL PRESENTATION 31	RAJAT PRABHAKAR PANDE	Exploring the efficacy of Systemic Inflammatory Markers in predicting outcomes post Transarterial Chemoembolization (c TACE & deb TACE)
24 April 2026, Friday	10:50 - 12:10	1416	ORAL PRESENTATION 31	Peng Chen	PPARα Activation Restores GSDME Pyroptosis to Reverse Anti–PD-1 Resistance in HCC
24 April 2026, Friday	10:50 - 12:10	1463	ORAL PRESENTATION 31	Yuta Maruki	Real-World Outcomes of Durvalumab Plus Tremelimumab (STRIDE) for Unresectable Hepatocellular Carcinoma in Japanese Patients
24 April 2026, Friday	10:50 - 12:10	1468	ORAL PRESENTATION 31	Jian-Hong Zhong	Multicenter evaluation of the efficacy and safety of rechallenge with immune checkpoint inhibitors in unresectable hepatocellular carcinoma
24 April 2026, Friday	17:10 - 18:30	2150	ORAL PRESENTATION 32	Asahiro Morishita	Early Skeletal Muscle Loss Predicts Poor Outcomes in Advanced Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy
24 April 2026, Friday	17:10 - 18:30	2161	ORAL PRESENTATION 32	Xi Zhang	Circulating Tumor DNA Analysis Enables Early Detection of Hepatocellular Carcinoma in High-Risk Patients
24 April 2026, Friday	17:10 - 18:30	2185	ORAL PRESENTATION 32	KAI-WEN HUANG	Nonthermal Histotripsy Enables Complete Ablation of Perivascular Liver Tumors While Preserving Adjacent Vessel Patency
24 April 2026, Friday	17:10 - 18:30	2215	ORAL PRESENTATION 32	Ning Wang	Innovative Insights: Hepatic Stellate Cells activation and ROS-Gene Signatures Predicting Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
24 April 2026, Friday	17:10 - 18:30	2254	ORAL PRESENTATION 32	Hiroki Tai	Prognostic Impact of Sarcopenia Assessed by Handgrip Strength and Skeletal Muscle Index in Hepatocellular Carcinoma Patients Receiving Atezolizumab plus Bevacizumab Therapy
24 April 2026, Friday	17:10 - 18:30	2290	ORAL PRESENTATION 32	Nitesh Kumar Karna	Coffee Consumption and Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses involving Over 12 Million Population
24 April 2026, Friday	17:10 - 18:30	2291	ORAL PRESENTATION 32	Wenxin Yan	The Antagonism between Demographic Shifts and Epidemiological Progress: A Decomposition Analysis of the Liver Cancer Burden in the Asia-Pacific, 1990–2023
24 April 2026, Friday	17:10 - 18:30	2329	ORAL PRESENTATION 32	Junjie Xu	Multi-omics analyses identify a novel hepatocellular carcinoma subtype with better response to immune checkpoint inhibitor therapies
24 April 2026, Friday	17:10 - 18:30	2351	ORAL PRESENTATION 32	Amarsanaa Jazag	A-HOC Study on Patients Under Real-time Surveillance for Liver Cancer in Mongolia
24 April 2026, Friday	10:50 - 12:10	1006	ORAL PRESENTATION 33	Jiahao Han	Ultrasound-derived Fat Fraction is a Reliable Method to Grade Hepatic Steatosis in Patients with Chronic Liver Diseases: A Multicenter Study in a Population with Mixed Etiologies
24 April 2026, Friday	10:50 - 12:10	1056	ORAL PRESENTATION 33	Eda Kaya	Development of a Predictive Formula for Hepatic Steatosis in Apparently Healthy Individuals: A Biopsy-Proven Study in Turkish Liver Transplant Donors
24 April 2026, Friday	10:50 - 12:10	2386	ORAL PRESENTATION 33	Anh Nguyen Thi Van	Immunosuppressive Medication Non-adherence in Liver Transplantation Adult Recipients in Vietnam
24 April 2026, Friday	10:50 - 12:10	2504	ORAL PRESENTATION 33	Devrim Muge Ozari Gulnar	Long-term outcomes of patients with Hepatitis D recurrence after liver transplantation
24 April 2026, Friday	10:50 - 12:10	2577	ORAL PRESENTATION 33	Yunzhi Shen	Using Rose to Improve the Accuracy of Diagnosis of Biliary Tract Diseases through ERCP guided Biopsy
24 April 2026, Friday	10:50 - 12:10	2695	ORAL PRESENTATION 33	Adem Kose	Candidemia in Liver Transplant Recipients: A Ten-Year Retrospective Study
24 April 2026, Friday	10:50 - 12:10	2699	ORAL PRESENTATION 33	emre aray	RAPID Procedure Enables Safe Use of Small Left Lobe Grafts: A Two-Center Experience
24 April 2026, Friday	10:50 - 12:10	2904	ORAL PRESENTATION 33	Jinzhen Cai	Clinical Analysis of Liver Transplantation in Patients With Severe Liver Disease
24 April 2026, Friday	10:50 - 12:10	2905	ORAL PRESENTATION 33	Jinzhen Cai	A clinical study on the reduction of donor lymphocyte chimerism rate in recipient tissues after liver transplantation by extracorporeal perfusion of anti-thymocyte globulin via portal vein
24 April 2026, Friday	18:30 - 20:00	2012	ORAL PRESENTATION 34	Deliang Huang	Eliminating Viral Hepatitis by 2030: Goals and Gaps from a Large-Scale Community-Based Study in Shenzhen, China
24 April 2026, Friday	18:30 - 20:00	2104	ORAL PRESENTATION 34	Zhengzhao Lu	A Longer Way to Go: Chronic Hepatitis B Burden and Trends Across the Asian-Pacific Region
24 April 2026, Friday	18:30 - 20:00	2105	ORAL PRESENTATION 34	Shauna MADIGAN	Breaking the habit: Evaluating the routine use of SBP prophylaxis
24 April 2026, Friday	18:30 - 20:00	2107	ORAL PRESENTATION 34	Terry Cheuk-Fung Yip	COVID-19 pandemic had minimal impact on the diagnostic and treatment uptakes for HCV – a territory-wide study
24 April 2026, Friday	18:30 - 20:00	2121	ORAL PRESENTATION 34	Hassan Mahmood	Eliminating Viral Hepatitis in Pakistan: A Comprehensive Strategic Framework
24 April 2026, Friday	18:30 - 20:00	2143	ORAL PRESENTATION 34	Huma Qureshi	A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad the federal capital of Pakistan

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
24 April 2026, Friday	18:30 - 20:00	2189	ORAL PRESENTATION 34	Shanshan Zhu	HBsAg Dynamics and Seroclearance Maintenance After Interferon Cessation in Chronic Hepatitis B Patients
24 April 2026, Friday	18:30 - 20:00	2229	ORAL PRESENTATION 34	Shaoqiu Zhang	Discrepancies in the indeterminate phase in patients with chronic hepatitis B between two updated international guidelines
24 April 2026, Friday	18:30 - 20:00	2240	ORAL PRESENTATION 34	İmran Hasanoglu	Hepatitis B Management in Primary Care: Nationwide Survey Highlights Knowledge and Practice Gaps Among Family Physicians in Turkiye
24 April 2026, Friday	18:30 - 20:00	1469	ORAL PRESENTATION 35	Yulong Shang	Targeting NEK9 in hepatocellular carcinoma to remodel immune microenvironment and enhance immunotherapy
24 April 2026, Friday	18:30 - 20:00	1473	ORAL PRESENTATION 35	Dongbo Chen	Dominant Neoantigens in Liver Cancer Malignant Ascites
24 April 2026, Friday	18:30 - 20:00	1493	ORAL PRESENTATION 35	Lu Li	Clinical determinants of treatment response in Asian hepatocellular carcinoma undergoing lenvatinib therapy: the impact of non-viral liver disease etiologies
24 April 2026, Friday	18:30 - 20:00	1516	ORAL PRESENTATION 35	Satoshi Narahara	Serum HBP as a Mechanistic Predictor of Primary Resistance to Atezolizumab plus Bevacizumab in HCC.
24 April 2026, Friday	18:30 - 20:00	1528	ORAL PRESENTATION 35	Matthew Shing-Hin Chung	Palliative care reduces disease time burden but is under-utilized in terminal-stage hepatocellular carcinoma
24 April 2026, Friday	18:30 - 20:00	1529	ORAL PRESENTATION 35	Zhengnan Cao	CD39 Promotes Angiogenesis and Poor Prognosis in Hepatocellular Carcinoma via Activation of the PI3K/AKT Signaling Pathway
24 April 2026, Friday	18:30 - 20:00	1552	ORAL PRESENTATION 35	Fengna Yan	Multi-Omics Integration Identifies a Prognostic Signature Guiding Precision Survival in Advanced HCC
24 April 2026, Friday	18:30 - 20:00	1564	ORAL PRESENTATION 35	Takeshi Okamoto	Second-line Therapy after Immunotherapy for Unresectable Hepatocellular Carcinoma: a Multicenter Data Registry Analysis
24 April 2026, Friday	18:30 - 20:00	1576	ORAL PRESENTATION 35	Yilan Yang	Qilingxiaoji formula and the effective ingredients inhibit hepatocellular carcinoma progression by inhibiting miR32/GPR180 signaling pathway
24 April 2026, Friday	18:30 - 20:00	2666	ORAL PRESENTATION 36	Dali Zhang	Outcomes of cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma after liver transplantation
24 April 2026, Friday	18:30 - 20:00	2678	ORAL PRESENTATION 36	Xi He	HBV recurrence in patients with hepatocellular carcinoma and cholangiocarcinoma following liver transplantation
24 April 2026, Friday	18:30 - 20:00	2679	ORAL PRESENTATION 36	Dali Zhang	Outcomes of cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma after liver transplantation
24 April 2026, Friday	18:30 - 20:00	2690	ORAL PRESENTATION 36	Yuhao Su	TACE plus Lenvatinib and Envafolimab for Conversion Therapy in Unresectable HCC: A Prospective, Phase II Study
24 April 2026, Friday	18:30 - 20:00	2739	ORAL PRESENTATION 36	Xuhua Duan	D-TACE Combined with HAIC Versus D-TACE in BCLC Stage C HCC: A Randomized Controlled Trial
24 April 2026, Friday	18:30 - 20:00	2753	ORAL PRESENTATION 36	Gulzar khan	Clinical and biochemical predictors of Hepatocellular Carcinoma: A Five-Year Cohort Study from a Tertiary Care Center in Pakistan
24 April 2026, Friday	18:30 - 20:00	2756	ORAL PRESENTATION 36	Hongli Yu	Locoregional Therapy Combined with Continuing or Switching Systemic Therapy for Intrahepatic Oligoprogression in Hepatocellular Carcinoma: A Multicenter Retrospective Study
24 April 2026, Friday	18:30 - 20:00	2784	ORAL PRESENTATION 36	Fuat Aksoy	The Effect of HALP Score on Predicting Post-Transplant Outcomes in Patients with Hepatocellular Carcinoma
24 April 2026, Friday	18:30 - 20:00	2809	ORAL PRESENTATION 36	Satı Coşkun Yazgan	Long-Term Survival in De Novo Liver-Metastatic Colorectal Cancer: A Descriptive Cohort Study
24 April 2026, Friday	18:30 - 20:00	1337	ORAL PRESENTATION 37	Qing Ye	Analysis of Factors Associated with Liver Fibrosis in Type 2 Diabetes Patients and the Predictive Value of CHI3L1 for Liver Fibrosis
24 April 2026, Friday	18:30 - 20:00	1352	ORAL PRESENTATION 37	Dang Toan Vo	Evaluation of Liver Fibrosis Using FIB-4 and ARFI in Non-Diabetic NAFLD Patients
24 April 2026, Friday	18:30 - 20:00	1401	ORAL PRESENTATION 37	Mst. Rejina Afrin	Effects of the secondary metabolites of Terminalia arjuna on non-alcoholic fatty liver disease in experimental mice model
24 April 2026, Friday	18:30 - 20:00	1417	ORAL PRESENTATION 37	Takefumi Kimura	The Clarity Trial: Prospective evaluation of pemafibrate therapy in MASLD
24 April 2026, Friday	18:30 - 20:00	1431	ORAL PRESENTATION 37	Siru Wu	Persistent sarcopenia confers a cumulative risk of fibrosis progression and liver-related events in biopsy-proven metabolic dysfunction-associated fatty liver disease
24 April 2026, Friday	18:30 - 20:00	1588	ORAL PRESENTATION 37	Zheng Liu	Role and Mechanism of TGFβ/pSAP Signaling in Regulating Hepatocyte-Macrophage Crosstalk in Metabolic Dysfunction-Associated Steatohepatitis
24 April 2026, Friday	18:30 - 20:00	1609	ORAL PRESENTATION 37	Yankun Gao	Prediction of Liver-Related Events Using Non-invasive Fibrosis Scores in Patients with Metabolic Dysfunction–Associated Fatty Liver Disease
24 April 2026, Friday	18:30 - 20:00	1615	ORAL PRESENTATION 37	Yi Xu	Mechanistic Study of Celiac Sympathetic Denervation in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
24 April 2026, Friday	18:30 - 20:00	1629	ORAL PRESENTATION 37	Ziyu Zhang	Analysis of Risk Factors and Establishment of a Predictive Model for Liver Disease Severity in Non-Alcoholic Fatty Liver Disease
24 April 2026, Friday	18:30 - 20:00	2256	ORAL PRESENTATION 38	Hafsa Abdul Waheed Jadgal	Efficacy of Combined Nutritional and Physical Activity Intervention in Reversing Early MAFLD
24 April 2026, Friday	18:30 - 20:00	2297	ORAL PRESENTATION 38	Kubra Koken	Ischemia-Modified Albumin in MASLD: Correlation With Ultrasonographic Steatosis Grade and Elastography-Based Liver Stiffness
24 April 2026, Friday	18:30 - 20:00	2310	ORAL PRESENTATION 38	Li Mingming	NAFLD promotes early hepatocellular carcinoma recurrence via MDSC metabolic reprogramming: Insights from a two-phase recurrence model in mice
24 April 2026, Friday	18:30 - 20:00	2328	ORAL PRESENTATION 38	DESIREE JANE LACUIN	Fatty Liver as a Key Risk Modifier for Adenoma Detection in FIT-Positive Young Adults: A Systematic Review of the Available Evidence
24 April 2026, Friday	18:30 - 20:00	2347	ORAL PRESENTATION 38	Jacob George	Semaglutide demonstrates efficacy in improving liver fibrosis across diverse subpopulations in part 1 of the ESSENCE trial – outcomes in Asian and non-Asian populations
24 April 2026, Friday	18:30 - 20:00	2374	ORAL PRESENTATION 38	Abdulvahap Hohluoğlu	Non-Invasive Assessment of Steatosis and Stiffness in MASLD: Links to Body Composition and Dyslipidemia in High-Risk Metabolic Groups
24 April 2026, Friday	18:30 - 20:00	2385	ORAL PRESENTATION 38	Rui Jin	HECTD3 Mediates PRDX4 Stabilization via K63-Linked Ubiquitination to Ameliorate Hepatic Steatosis, Inflammation, and Fibrosis in MASH
24 April 2026, Friday	18:30 - 20:00	2426	ORAL PRESENTATION 38	Yixuan Zhu	Association of Immune Nutritional Status with Histological Stage and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Population-Based Cohort Study
24 April 2026, Friday	18:30 - 20:00	2559	ORAL PRESENTATION 38	Chenlu Yang	Evaluation of a FIB-4–Based Clinical Pathway for Fibrosis Assessment in Patients with Coronary Heart Disease
24 April 2026, Friday	18:30 - 20:00	2574	ORAL PRESENTATION 39	Ammal Metwally	Plasma microRNA-based non-invasive stratification of clinically significant and advanced fibrosis in metabolic dysfunction-associated steatotic liver disease among Arab adults
24 April 2026, Friday	18:30 - 20:00	2609	ORAL PRESENTATION 39	Huiling Cao	Acetylation modification of PKM2 promotes macrophage reprogramming and accelerates the progression of MAFLD
24 April 2026, Friday	18:30 - 20:00	2614	ORAL PRESENTATION 39	Zhongji Meng	A Cross-Section Study on the Co-prevalence of MAFLD and HBV Infection Among Adult Residents in Maojian District, Shiyan City.
24 April 2026, Friday	18:30 - 20:00	2617	ORAL PRESENTATION 39	Feihu Bai Bai Feihu	Spirulina Prevents Hepatic Steatosis by Promoting Macrophage M2 Polarization via Gut Microbiota-Derived 2-Hydroxy-3-Methylbutyrate
24 April 2026, Friday	18:30 - 20:00	2620	ORAL PRESENTATION 39	Daya Zhang Zhang Daya	The Gut Fungus Rhizopus microsporus var. rhizopodiformis Exacerbates Metabolic-associated Fatty Liver Disease by Impairing Intestinal Barrier Integrity
24 April 2026, Friday	18:30 - 20:00	2623	ORAL PRESENTATION 39	ZHU XIAONING	Transcriptomic Profiling Identifies Anti-Inflammatory and Anti-Steatotic Programs Mediated by ShenGe Formula in MAFLD
24 April 2026, Friday	18:30 - 20:00	2626	ORAL PRESENTATION 39	Chunyan Wang	Clinical characteristics of colorectal polyps in patients with non-alcoholic fatty liver disease in high altitude areas
24 April 2026, Friday	18:30 - 20:00	2641	ORAL PRESENTATION 39	Eman Fares	Prevalence of Metabolic-Associated Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Cross-Sectional Study
24 April 2026, Friday	18:30 - 20:00	2643	ORAL PRESENTATION 39	Jiawei Cui	IL-24 attenuates hepatocyte apoptosis and ameliorates metabolic-associated steatohepatitis by activating the autophagy-lysosome pathway
24 April 2026, Friday	18:30 - 20:00	1414	ORAL PRESENTATION 40	Sanju Yadav	Multi-omics integration analysis identifies Molecular Signatures of Liver Stress in preclinical model of Acute Hypoxia
24 April 2026, Friday	18:30 - 20:00	1484	ORAL PRESENTATION 40	Ceylan KÜPELİ	Exploring the Anticancer Effects of Spirulina Extract in Human Hepatocellular Carcinoma Cells
24 April 2026, Friday	18:30 - 20:00	1677	ORAL PRESENTATION 40	Eman El-Ahwany	Establishment of the TBRI Biobank for Liver Diseases: Advancing Research Translation and Precision Medicine in Hepatology
24 April 2026, Friday	18:30 - 20:00	1698	ORAL PRESENTATION 40	rajaa boukhraiss	Etiological Predictors of Portal Vein Thrombosis in Patients with Porto-Sinusoidal Vascular Disease
24 April 2026, Friday	18:30 - 20:00	1781	ORAL PRESENTATION 40	Jiahao Yuan	An Endothelial-Related Gene Signature Derived from Integrative Transcriptomics Predicts HCC in Cirrhosis
24 April 2026, Friday	18:30 - 20:00	1812	ORAL PRESENTATION 40	Weihua Cao	Clinical characteristics and influencing factors of porto-sinusoidal vascular disease patients with metabolic dysfunction-associated steatotic liver disease
24 April 2026, Friday	18:30 - 20:00	2815	ORAL PRESENTATION 40	Nicholas Dunn	Associations Between Dietary recommendations/ diet quality and Steatotic Liver Disease Prevalence and Severity in U.S. Adults 2017–2023
24 April 2026, Friday	18:30 - 20:00	2833	ORAL PRESENTATION 40	Huilian Shi	Hyperinsulinemia Establishes a Pathogenic Feedback Loop between Pyroptotic Hepatocytes and MDSCs in MAFLD
24 April 2026, Friday	18:30 - 20:00	2878	ORAL PRESENTATION 40	Krisanto Tanjaya	From Stool to Personalized Screening Approach: A Comprehensive Meta-analysis of Metagenomic Gut Microbiota Assessment in Patient with MAFLD and Control Cohort
24 April 2026, Friday	18:30 - 20:00	1159	ORAL PRESENTATION 41	Lujie Liu	Gut Microbiota-Derived CoQ8 Improves Hepatic Lipid Metabolism via GPR120
24 April 2026, Friday	18:30 - 20:00	2488	ORAL PRESENTATION 41	Lajpat Rai	SAFETY OF MIDAZOLAM AND NALBUPHINE IN CIRRHOTIC PATIENTS WHO UNDERGO UPPER GASTROINTESTINAL ENODSCOPY
24 April 2026, Friday	18:30 - 20:00	2554	ORAL PRESENTATION 41	Jayadevan K	A Preclinical study on Protective Effects of Atorvastatin Against Methotrexate-Induced Hepato-Renal Toxicity: Role of Oxidative Stress and Inflammation

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
24 April 2026, Friday	18:30 - 20:00	2562	ORAL PRESENTATION 41	Irshad Batool	Successful Endoscopic Ultrasound–Guided Ethanol Ablation of a 7-mm Non-Functional Pancreatic Neuroendocrine Tumor in a High-Risk Surgical Candidate
24 April 2026, Friday	18:30 - 20:00	2634	ORAL PRESENTATION 41	Yingying Nie	A Novel Murine Model of MetALD Recapitulates the Synergistic and Aggressive Phenotype of Combined Metabolic Dysfunction and Alcohol Consumption
24 April 2026, Friday	18:30 - 20:00	2640	ORAL PRESENTATION 41	Mehmet Demir	Necrolytic migratory erythema without glucagonoma: An unusual association with chronic pancreatitis and hepatic dysfunction
24 April 2026, Friday	18:30 - 20:00	2733	ORAL PRESENTATION 41	Runci Jiang	Joint Association of C-Reactive Protein and the Triglyceride Glucose–Chinese Visceral Adiposity Index with Incident Chronic Liver Disease: A National Cohort Study
24 April 2026, Friday	18:30 - 20:00	2748	ORAL PRESENTATION 41	Mario Rafael Estella	A Retrospective Cohort Study on the Adherence to American Association for the study of Liver Diseases (AASLD) Quality Measures in Cirrhosis for Variceal Bleeding and its Association with Clinical Outcomes
24 April 2026, Friday	18:30 - 20:00	2848	ORAL PRESENTATION 41	Hong-Li Liu	Physician–Patient Dual-Track Follow-Up Care Bundle in Hepatology: A Multidisciplinary Practice Model Integrating Clinical Care and Research Coordination
25 April 2026, Saturday	07:30 - 09:00	1954	ORAL PRESENTATION 42	Fatih Albayrak	Effects of Obinutuzumab on Cecal Ligation and Puncture Induced Septic Liver Injury in Rats
25 April 2026, Saturday	07:30 - 09:00	2028	ORAL PRESENTATION 42	Peng Qu	sepsis
25 April 2026, Saturday	07:30 - 09:00	2100	ORAL PRESENTATION 42	Maisam Akroush	From Organ to Surface: Perforating Disorders in Chronic Liver Disease
25 April 2026, Saturday	07:30 - 09:00	2152	ORAL PRESENTATION 42	Qiankun Hu	Circulating cell-free mitochondrial DNA predicts prognosis and triggers macrophage STING-dependent inflammation in acute-on-chronic liver failure
25 April 2026, Saturday	07:30 - 09:00	2195	ORAL PRESENTATION 42	Xueyun Zhang	3D Radiomics Analysis Based on Liver CT Imaging for Predicting Hepatic Encephalopathy in HBV-ACLF Patients
25 April 2026, Saturday	07:30 - 09:00	2218	ORAL PRESENTATION 42	Shan Zhong	Nucleos(t)ide Analogue Treatment History Stratifies Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
25 April 2026, Saturday	07:30 - 09:00	2292	ORAL PRESENTATION 42	Iufeng LI	Analysis of Clinical Characteristics and Treatment Outcomes in HBV - Related Liver Failure Patients with or without Diabetes Mellitus
25 April 2026, Saturday	07:30 - 09:00	2508	ORAL PRESENTATION 42	Anand Kulkarni	Midodrine with albumin improves ascites control in Acute-on-chronic liver failure: A Double Bind Randomized trial (MIDAS trial)
25 April 2026, Saturday	07:30 - 09:00	2527	ORAL PRESENTATION 42	Pelin Telli	Prognostic Stratification of Non-Ischemic Acute Liver Injury in the Emergency Department: A Retrospective Cohort Study
25 April 2026, Saturday	07:30 - 09:00	1085	ORAL PRESENTATION 43	Fatih Işık	Radiomics on Gadoxetic Acid HBP MRI to Distinguish Subclinical Hepatic Parenchymal Disease from Normal Liver
25 April 2026, Saturday	07:30 - 09:00	1123	ORAL PRESENTATION 43	Shifan Liu	From Cirrhosis to Cancer: End-to-End Deep Learning Surveillance on Non-Contrast CT
25 April 2026, Saturday	07:30 - 09:00	1125	ORAL PRESENTATION 43	Hatice OGUR	Development of an Explainable Hybrid Artificial Intelligence System for Early Detection of Chronic Liver Diseases
25 April 2026, Saturday	07:30 - 09:00	2525	ORAL PRESENTATION 43	Federico Peralta	Adherence to an Admission Care Bundle and Its Impact on Outcomes in Decompensated Cirrhosis: A Multicenter Analytical Cross-Sectional Study
25 April 2026, Saturday	07:30 - 09:00	2602	ORAL PRESENTATION 43	GİZEM DAĞCI	Effect of Midodrine on Short Term Mortality and Liver Function in Patients with Cirrhosis and Ascites: A Systematic Review and Meta-analysis
25 April 2026, Saturday	07:30 - 09:00	2660	ORAL PRESENTATION 43	Md. Shakhawat Hossain	The Silent Summer Threat: Significant Seasonal Worsening of Electrolyte Imbalance in Cirrhosis Patients in a Tropical Climate Calls for Dynamic Diuretic Dosing
25 April 2026, Saturday	07:30 - 09:00	2672	ORAL PRESENTATION 43	JAYASHREE BISWAS	Predictors of Post-TIPS Persistent Ascites
25 April 2026, Saturday	07:30 - 09:00	2691	ORAL PRESENTATION 43	Sayan Malakar	Splenic Stiffness Measurement to PREdict Decompensation in Patients with Compensated Advanced Chronic Liver Disease in India (SPRED-c-ACLD study)
25 April 2026, Saturday	07:30 - 09:00	2736	ORAL PRESENTATION 43	Manu Rajeev	Thalidomide reduces transfusion requirements due to gastrointestinal vascular malformations in patients with liver cirrhosis
25 April 2026, Saturday	07:30 - 09:00	1072	ORAL PRESENTATION 44	Vahe Azatyan	Comparative evaluation of the level of oral microflora in patients with viral hepatitis C using heated tobacco product and cigarette smoking in Armenia: a pilot study
25 April 2026, Saturday	07:30 - 09:00	1144	ORAL PRESENTATION 44	Akshit Vats	The GREM1–BMP7 axis orchestrates apoptosis-driven fibrotic remodeling in biliary atresia
25 April 2026, Saturday	07:30 - 09:00	1378	ORAL PRESENTATION 44	Nupur Sharma	Leucine-rich alpha-2-glycoprotein 1 turnover imbalance impairs regenerative signaling in Alcohol-associated Hepatitis
25 April 2026, Saturday	07:30 - 09:00	1625	ORAL PRESENTATION 44	Yu Zhang	Alcohol Consumption Accelerates Liver Fibrosis in Chronic Hepatitis B: Evidence from Mendelian Randomization and a Prospective Cohort Study
25 April 2026, Saturday	07:30 - 09:00	1634	ORAL PRESENTATION 44	Yifan Xu	Integrated Plasma and Fecal Metabolic Profiling in Alcoholic Cirrhosis: Association with Gut Microbiota Dysbiosis
25 April 2026, Saturday	07:30 - 09:00	1735	ORAL PRESENTATION 44	Mohit Varshney	Policy Blind Spots and Clinical Realities: Determinants of Continued Alcohol Use in Alcohol-Associated Liver Disease at India's First Integrated AUD–ALD Clinic
25 April 2026, Saturday	07:30 - 09:00	1754	ORAL PRESENTATION 44	Qi Shen Shen	The mechanism of TMBIM5 in ameliorating alcohol-related liver disease by regulating mitochondrial dynamics
25 April 2026, Saturday	07:30 - 09:00	2541	ORAL PRESENTATION 44	Hasan Buran	Alcoholic Liver Transplants Performed Due to Liver Disease: A Single-Center Experience
25 April 2026, Saturday	07:30 - 09:00	2886	ORAL PRESENTATION 44	Pavithra Senadheera	Comparative Analysis of Epidemiological Research Output: Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Alcohol-Associated Liver Disease
25 April 2026, Saturday	07:30 - 09:00	1025	ORAL PRESENTATION 45	Jun-Hao Mei	Real-time multidimensional system for predicting survival in patients with advanced biliary tract cancer treated with immuno-chemotherapy
25 April 2026, Saturday	07:30 - 09:00	1110	ORAL PRESENTATION 45	Mark Angelo Pado	Effectiveness and safety of Fibrate Therapy in the treatment of adults with Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis
25 April 2026, Saturday	07:30 - 09:00	1257	ORAL PRESENTATION 45	Yu Huang	Si-Ni-San, a traditional Chinese herbal formula, ameliorates cholestatic liver injury by targeting the calcium-sensing receptor (CaSR)/MAPK pathway
25 April 2026, Saturday	07:30 - 09:00	1418	ORAL PRESENTATION 45	Li Wei	Efficacy of Sulfasalazine in Patients with Primary Biliary Cholangitis and Incomplete Response to Ursodeoxycholic Acid
25 April 2026, Saturday	07:30 - 09:00	1482	ORAL PRESENTATION 45	Jing Liang	From Gene Expression Profiles to Functional Networks: A Multi-Omics Integrative Analysis of Methyl Eugenol Promoting Cholangiocarcinoma Development
25 April 2026, Saturday	07:30 - 09:00	2368	ORAL PRESENTATION 45	Abhishak GUPTA	Dynamic Metabolic Reprogramming Drives Adipose Fibrosis in a High-Fat Diet–Induced Obesity in Mice Model
25 April 2026, Saturday	07:30 - 09:00	2406	ORAL PRESENTATION 45	Jing Chen	Benefit of treatment expansion: A Comparative Analysis of EASL 2025, AASLD 2025, and APASL 2026 Clinical Practice Guidelines for Management of Chronic Hepatitis B
25 April 2026, Saturday	07:30 - 09:00	2461	ORAL PRESENTATION 45	Mohamed Elsaid	Early GI/Hepatology Subspecialty Access in Cirrhosis and Survival: A Retrospective Cohort Analysis
25 April 2026, Saturday	07:30 - 09:00	2673	ORAL PRESENTATION 45	Yuyuan Jia	Parallel Comparison of Two HBV pg RNA Detection Assays
25 April 2026, Saturday	07:30 - 09:00	1619	ORAL PRESENTATION 46	Qing-Lei Zeng	Safety and Effectiveness of Peginterferon Alfa-2b Combined with Tenofovir Amibufenamide in Patients with Chronic Hepatitis B
25 April 2026, Saturday	07:30 - 09:00	1646	ORAL PRESENTATION 46	Yuxi Shi	Mapping the Global Network of Viral Hepatitis A, B, C and E: Unveiling Disease-Specific Epidemic Architectures through Complex Network Analysis
25 April 2026, Saturday	07:30 - 09:00	1647	ORAL PRESENTATION 46	Mingyang Feng	Antiviral Therapy in Patients with HBV Infection in the HBeAg-Negative Indeterminate Phase
25 April 2026, Saturday	07:30 - 09:00	1653	ORAL PRESENTATION 46	Menghan Jin	Efficacy of sofosbuvir/velpatasvir in patients with hepatitis C virus genotype 3 infection
25 April 2026, Saturday	07:30 - 09:00	1661	ORAL PRESENTATION 46	Zain Majid	Clinical Characteristics of Autoimmune Hepatitis in Patients with Hepatitis B–D Coinfection: A Case Series
25 April 2026, Saturday	07:30 - 09:00	1664	ORAL PRESENTATION 46	Hua-xiang Yang	Matrix Stiffness Suppresses Hepatitis B Virus Replication via YAP-Mediated Intrinsic Antiviral Signaling
25 April 2026, Saturday	07:30 - 09:00	1673	ORAL PRESENTATION 46	Pius Takyi	Towards hepatitis B elimination in Ghana: vaccination coverage and its predictors among informal sector workers in Kejetia, Kumasi, Ghana
25 April 2026, Saturday	07:30 - 09:00	1690	ORAL PRESENTATION 46	Petek Şarlak Konya	Off-Therapy Outcomes After Long-Term Nucleos(t)ide Analogue Treatment in HBeAg-Negative Chronic Hepatitis B
25 April 2026, Saturday	07:30 - 09:00	1694	ORAL PRESENTATION 46	Hamza Benazzouz	Non-Invasive Evaluation of Fibrosis Regression in HBV and HCV: A Real-World Comparative Analysis
25 April 2026, Saturday	07:30 - 09:00	1023	ORAL PRESENTATION 47	Ajay Patwa	Real-world Clinical and Procedural Insights into Liver Abscesses: A Multidimensional Retrospective Analysis from a Tertiary Center in North India
25 April 2026, Saturday	07:30 - 09:00	1820	ORAL PRESENTATION 47	Chihiro Miwa	Downstaging by Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma: Identifying Candidates for Conversion Therapy Based on Tumor Biology and Vascular Invasion Patterns
25 April 2026, Saturday	07:30 - 09:00	1918	ORAL PRESENTATION 47	James Manuel Medalla	Solving a Recurrent Hepatic Abscesses Through Discovery of a Cholecystoduodenal Fistula resulting from an Over-the-Scope Clip closure of Duodenal Perforation as a complication of Microwave Ablation for HCC
25 April 2026, Saturday	07:30 - 09:00	2092	ORAL PRESENTATION 47	Yu Jun Wong	Paris-II Outperforms Other UDCA Response Criteria to predict Transplant-Free Survival in Asian PBC Patients
25 April 2026, Saturday	07:30 - 09:00	2102	ORAL PRESENTATION 47	Abhimati Ravikulan	Temporal Trends and Outcomes of AMA-Negative Primary Biliary Cholangitis in a Multi-Centre South-East Asian Cohort
25 April 2026, Saturday	07:30 - 09:00	2192	ORAL PRESENTATION 47	Xinghuan Fu	Neutrophil recruited CD38hi cytotoxic CD8 T cells characterize the T cell infiltrate in checkpoint inhibitor-mediated cholangitis
25 April 2026, Saturday	07:30 - 09:00	2225	ORAL PRESENTATION 47	Emerald T. Gersava	Infected Choledochal Cysts Masking as Liver Abscesses in an Adult Male: A Case Report
25 April 2026, Saturday	07:30 - 09:00	2440	ORAL PRESENTATION 47	Kedsiree Sanit	Clinical outcomes and treatment response in primary biliary cholangitis with and without autoimmune hepatitis features: a Thai multicenter 10-year cohort
25 April 2026, Saturday	07:30 - 09:00	2832	ORAL PRESENTATION 47	Rino Alvani Gani	Immune-Excluded CD4⁺ and CD8⁺ T-Cell Depletion Predicts Early Recurrence in Hepatocellular Carcinoma with Microvascular Invasion

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
25 April 2026, Saturday	07:30 - 09:00	1607	ORAL PRESENTATION 48	Zhewen Zhou	From Dysbiosis to Prediction: A Novel Gut Microbiota–Derived Index for Spontaneous Bacterial Peritonitis in HBV-Related Cirrhosis
25 April 2026, Saturday	07:30 - 09:00	1608	ORAL PRESENTATION 48	Lei Shi	Two-Year Follow-up of a Dose-Escalation Trial of Mesenchymal Stromal Cell Therapy for Decompensated Liver Cirrhosis
25 April 2026, Saturday	07:30 - 09:00	1624	ORAL PRESENTATION 48	Chenglin Sun	A Noninvasive Model Based on Liver and Spleen Microcirculatory Perfusion Parameters for Predicting High-Risk Varices in CHB-Related Cirrhosis
25 April 2026, Saturday	07:30 - 09:00	1662	ORAL PRESENTATION 48	Md. Sabbir Hossain	Socioeconomic Disparities and Potential Impact of Delayed Presentation on the Burden of Portal Hypertension in a Bangladeshi Tertiary Care Setting
25 April 2026, Saturday	07:30 - 09:00	1713	ORAL PRESENTATION 48	Han Ding	Hepatocyte myb-like swirm and mpn domains 1 exacerbates liver fibrosis by stabilizing gelsolin via k29-linked deubiquitination
25 April 2026, Saturday	07:30 - 09:00	1715	ORAL PRESENTATION 48	Eman Abdelsameea	THE OUTCOME PREDICTION ROLE OF RED CELL DISTRIBUTION WIDTH IN 1000 HOSPITALIZED CIRRHOTIC EGYPTIAN PATIENTS
25 April 2026, Saturday	07:30 - 09:00	1727	ORAL PRESENTATION 48	Riad Mohammad Moshaed Hossain	Diagnosis of the differentials of ascites in low-resource settings.
25 April 2026, Saturday	07:30 - 09:00	1769	ORAL PRESENTATION 48	UDIT VAISH	Admission NLR and APRI as Practical, Low-Cost Predictors of Severity in Cirrhosis: Data from an Indian Tertiary Center
25 April 2026, Saturday	07:30 - 09:00	1771	ORAL PRESENTATION 48	Hak Keith Leung	Our Journey Towards a Dedicated Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Service: Teamwork Makes the Dream Work
25 April 2026, Saturday	07:30 - 09:00	2463	ORAL PRESENTATION 49	Paul Miguel Perez	Association of Long-Term Glycemic Control with the Risk of Developing Cirrhosis in Type 2 Diabetes Mellitus: A 5-Year Multi-Center Retrospective Cohort Study of Liver Outcomes and Predictive Factors
25 April 2026, Saturday	07:30 - 09:00	2534	ORAL PRESENTATION 49	ALYSSA CHAN	ASSESSMENT OF ACCURACY OF PLATELET COUNT/SPLEEN DIAMETER RATIO IN PREDICTING THE PRESENCE OF ESOPHAGEAL VARICES IN FILIPINO PATIENTS WITH CIRRHOSIS AT SLMC-QC
25 April 2026, Saturday	07:30 - 09:00	2543	ORAL PRESENTATION 49	Sam Fandood	Prevalence and risk factors of esophageal and gastroesophageal varices in myeloproliferative neoplasm patients with portal hypertension in a tertiary government hospital: a 5-year cross-sectional study
25 April 2026, Saturday	07:30 - 09:00	2593	ORAL PRESENTATION 49	Cheng Zeng	Spermidine suppresses liver fibrosis by remodeling the communication signal between liver sinusoidal endothelial cells and hepatic stellate cells Running title: Spermidine suppresses liver fibrosis by downregulation of LSEC-derived BGN
25 April 2026, Saturday	07:30 - 09:00	2594	ORAL PRESENTATION 49	Runling Zhang	Risk factors for low-level viremia in Tenofovir Disoproxil Fumarate (TDF)-treated patients with chronic hepatitis B complicated by advanced hepatic fibrosis/compensated liver cirrhosis
25 April 2026, Saturday	07:30 - 09:00	2605	ORAL PRESENTATION 49	Yang Liu	Mobile Ablation for Secondary Hypersplenism in Hepatocellular Carcinoma Patients with Liver Cirrhosis: A Safety and Efficacy Study
25 April 2026, Saturday	07:30 - 09:00	2607	ORAL PRESENTATION 49	Jingyu Zhang	Inhibition of FKBP10 attenuates hepatic stellate cell activation and liver fibrosis via RAS signaling
25 April 2026, Saturday	07:30 - 09:00	2612	ORAL PRESENTATION 49	SAUL SUAYBAGUIO	Accuracy of D-dimer Levels in Predicting Clinical Outcomes of Patients with Decompensated Liver Cirrhosis in a Philippine Tertiary Hospital
25 April 2026, Saturday	07:30 - 09:00	2625	ORAL PRESENTATION 49	Jeremie Manarang	Procedural-Related Bleeding Among Patients with Liver Cirrhosis in a Tertiary Hospital in the Philippines: A Five-Year Review
25 April 2026, Saturday	09:00 - 10:30	1725	ORAL PRESENTATION 50	Ruifeng Yang	Suboptimal sensitivity of quantitative HBcrAg assay for managing HBeAg-negative chronic hepatitis B
25 April 2026, Saturday	09:00 - 10:30	1738	ORAL PRESENTATION 50	Yuying Chen	Combination Therapy with Toll-like receptor 7 Agonist and Programmed Death Ligand 1 Antibody Restores HBV-Specific CD8+T Cells in Virally suppressed Chronic Hepatitis B
25 April 2026, Saturday	09:00 - 10:30	1747	ORAL PRESENTATION 50	Jian Wu	Predictive Biomarkers for Hepatitis E Virus-Related Acute Liver Failure Based on Lipidomics and Transcriptomics
25 April 2026, Saturday	09:00 - 10:30	1753	ORAL PRESENTATION 50	Jason Phowira	Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Cirrhosis Caused by Hepatitis B: A Single-Center Case Series
25 April 2026, Saturday	09:00 - 10:30	1776	ORAL PRESENTATION 50	Sujun Zheng	Immune characteristics of peripheral blood cells in inactive hepatitis B surface antigen carriers treated with interferon
25 April 2026, Saturday	09:00 - 10:30	1782	ORAL PRESENTATION 50	Sharker Mohammad Shahadat Hossain	An Evaluation of the Effectiveness of Entecavir in Patients with Acute Chronic Hepatitis B liver Failure
25 April 2026, Saturday	09:00 - 10:30	1802	ORAL PRESENTATION 50	Man Li	Hesperidin inhibits HBV via promoting macrophage M1 polarization through activation of the NF-κB/CXCL/TNFα pathway
25 April 2026, Saturday	09:00 - 10:30	1819	ORAL PRESENTATION 50	Ahmet Sertçelik	Impact of the expanded program on immunization on Hepatitis B elimination efforts: Insights from a Turkish reference center
25 April 2026, Saturday	09:00 - 10:30	1822	ORAL PRESENTATION 50	Xin Wang	Blood biomarkers for non-invasive diagnosis of advanced fibrosis or compensated cirrhosis in chronic hepatitis B
25 April 2026, Saturday	09:00 - 10:30	2635	ORAL PRESENTATION 51	Yuzhu Song	Endothelial RGS16 Attenuates Hepatic Fibrosis by Restricting Pathological
25 April 2026, Saturday	09:00 - 10:30	2654	ORAL PRESENTATION 51	Qiang Li	Comparison of the diagnostic accuracy of magnetic resonance elastography, FibroScan, and serum fibrosis models for detecting liver fibrosis and cirrhosis in chronic liver diseases: a multicohort study across all aetiologies
25 April 2026, Saturday	09:00 - 10:30	2670	ORAL PRESENTATION 51	Changqing Guo	Endoscopic Ultrasound-Guided Partial Splenic Embolization in Hypersplenism: A Novel Approach Validated in a pilot study
25 April 2026, Saturday	09:00 - 10:30	2706	ORAL PRESENTATION 51	Haiyu Wang	A Novel Non-invasive Model to Identify High Risk Varices in Patients with HBV-related Cirrhosis
25 April 2026, Saturday	09:00 - 10:30	2731	ORAL PRESENTATION 51	Chihao Zhang	Tbx1 alleviated hepatic encephalopathy by promoting meningeal lymphangiogenesis and drainage of senescent astrocytes via a CCL21-dependent manner
25 April 2026, Saturday	09:00 - 10:30	2781	ORAL PRESENTATION 51	EINA MARIE LI	Dual noninvasive prediction of esophageal varices in cirrhosis using transient elastography and echocardiographic parameters: an interim machine learning analysis
25 April 2026, Saturday	09:00 - 10:30	2799	ORAL PRESENTATION 51	Zhandong Lin	Cathepsin K Attenuates Liver Fibrosis by Suppressing TGF-β/Smad Signaling via TβR-I Degradation
25 April 2026, Saturday	09:00 - 10:30	2810	ORAL PRESENTATION 51	Sajid Jalil	Sodium Glucose Co-Transporter 2 Inhibitors Use in Diabetic Patients with Cirrhosis Improves Liver-related Outcomes and Survival
25 April 2026, Saturday	10:50 - 12:10	2276	ORAL PRESENTATION 52	Jian Wang	Long-Term Outcomes of Treatment-Induced Versus Spontaneously Achieved HBsAg <100 IU/mL in Chronic Hepatitis B
25 April 2026, Saturday	10:50 - 12:10	2282	ORAL PRESENTATION 52	Leer Shen	SIRT2 restrains HDV-associated hepatic macrophage pyroptosis by deacetylating NLRP3 and suppressing NF-κB signaling
25 April 2026, Saturday	10:50 - 12:10	2294	ORAL PRESENTATION 52	Elif Gucyetmez	Comparison of the Effects of Tenofovir Alafenamide and Entecavir on Lipid Profiles in Anti-HBc Positive Kidney Transplant Recipients
25 April 2026, Saturday	10:50 - 12:10	2306	ORAL PRESENTATION 52	Yanwei Zhong	Study on Key Inflammatory Proteins of Antiviral Treatment in Children with Chronic Hepatitis B
25 April 2026, Saturday	10:50 - 12:10	2377	ORAL PRESENTATION 52	Yaqin Zhang	Efficacy Differences of Interferon Combined with Nucleos(t)ide Analogs in Treating HBeAg-Positive Chronic Hepatitis B Stratified by Baseline Liver Fibrosis Indicators
25 April 2026, Saturday	10:50 - 12:10	2389	ORAL PRESENTATION 52	Qiran Zhang	Towards Individualized Interferon Therapy in Hepatitis B: HBsAg Kinetics and Seroclearance upon Baseline HBsAg Levels and Treatment Duration
25 April 2026, Saturday	10:50 - 12:10	2404	ORAL PRESENTATION 52	Chao Jiang	Development and validation of a dynamic nomogram for predicting significant liver injury in chronic hepatitis B patients with indeterminate phase
25 April 2026, Saturday	10:50 - 12:10	2410	ORAL PRESENTATION 52	Ruirui You	Hepatitis B Virus Core Antibody Seroconversion and Risk of Hepatitis B Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation
25 April 2026, Saturday	10:50 - 12:10	2457	ORAL PRESENTATION 52	Yelda Öğütmen	Impact of the national Hepatitis B vaccination program on HBsAg seroprevalence in pregnant women and comparison with migrant pregnant women
25 April 2026, Saturday	10:50 - 12:10	1580	ORAL PRESENTATION 53	ALİ ÇAĞRI ORAL	Prognostic Evaluation of Hepatocellular Carcinoma: Impact of Etiological Factors on Survival Outcomes
25 April 2026, Saturday	10:50 - 12:10	1581	ORAL PRESENTATION 53	Hongli Yu Yu	Continuing or Switching Systemic Therapy Combined with Locoregional Therapy Defines a Personalized Strategy for Oligoprogression in HCC: A Multicenter Retrospective Study
25 April 2026, Saturday	10:50 - 12:10	1592	ORAL PRESENTATION 53	Abdel Ghani Atef Abdel Ghani Badran	Fibroscan role in determining the patients who are at high risk for developing HCC in 1000 cirrhotic Egyptian patients.
25 April 2026, Saturday	10:50 - 12:10	1596	ORAL PRESENTATION 53	Minjun liao	ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with Bevacizumab and Sintilimab therapy
25 April 2026, Saturday	10:50 - 12:10	1603	ORAL PRESENTATION 53	Qianting Guan	FcγRⅡB mediates CD8+ T cells dysfunction in Hepatocellular Carcinoma
25 April 2026, Saturday	10:50 - 12:10	1640	ORAL PRESENTATION 53	Xiangchang Zeng	The β-hydroxybutyrylation modification of ACSL4 inhibits the growth of hepatocellular carcinoma
25 April 2026, Saturday	10:50 - 12:10	1676	ORAL PRESENTATION 53	Hayriye Dilan Çağlar	Predictive Factors of Tyrosine Kinase Inhibitor Response in Patients with Advanced Hepatocellular Carcinoma
25 April 2026, Saturday	10:50 - 12:10	1757	ORAL PRESENTATION 53	Yeo Wool Kang	Impact of etiology on outcomes with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter propensity-matched analysis
25 April 2026, Saturday	10:50 - 12:10	1758	ORAL PRESENTATION 53	Yue Huang	Predictive Role of Spleen Stiffness in Gastrointestinal Bleeding for Patients with Unresectable Hepatocellular Carcinoma Undergoing Systemic Therapy
25 April 2026, Saturday	10:50 - 12:10	1949	ORAL PRESENTATION 54	Mohammad Shariq	Development and Evaluation of Polyherbal Chitosan Nanoparticles: Antioxidant and Cytotoxic Effects on HepG2 Cells
25 April 2026, Saturday	10:50 - 12:10	1985	ORAL PRESENTATION 54	Ayşegül Öztürk	Effects of Linalool–Regorafenib Combination on Anticancer Activity in HUH-7 Cells
25 April 2026, Saturday	10:50 - 12:10	2000	ORAL PRESENTATION 54	Wanxin Shi	Efficacy of Yangyin Fuzheng Jiedu Prescription for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: An Evaluation Using Five Propensity Score Methods
25 April 2026, Saturday	10:50 - 12:10	2067	ORAL PRESENTATION 54	Jinpeng Li	Hepatic Arterial Infusion Chemotherapy Combined with Donafenib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma with Lung Metastases: A Multicenter Retrospective Study
25 April 2026, Saturday	10:50 - 12:10	2081	ORAL PRESENTATION 54	Mohammad Forhad Abedin Abedin	Late Presentation and Poor Outcomes of Hepatocellular Carcinoma in a Resource-Limited Setting: An Observational Study in a Tertiary Care Hospital, Bangladesh
25 April 2026, Saturday	10:50 - 12:10	2083	ORAL PRESENTATION 54	Cun Wang	Targeting STK40 unleashes anti-tumor immunity by triggering tumor vulnerability and T cell reinvigoration
25 April 2026, Saturday	10:50 - 12:10	2094	ORAL PRESENTATION 54	Xuhui Ma	Inhibition of Aurora B Induces Senescence and Potentiates Immunotherapy in Hepatocellular Carcinoma

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
25 April 2026, Saturday	10:50 - 12:10	2113	ORAL PRESENTATION 54	Chen Yang	Unveiling occult squamous commitment as a clinical fate determinant in cholangiocarcinoma
25 April 2026, Saturday	10:50 - 12:10	2124	ORAL PRESENTATION 54	Abdul Samad Bhatti	GENDER DISPARITIES IN HEPATOCELLULAR CARCINOMA: A COMPARATIVE ANALYSIS
25 April 2026, Saturday	10:50 - 12:10	1069	ORAL PRESENTATION 55	Baoju Wang	Gut Microbiota-Derived Butyrate Alleviates the Progression of Metabolic Dysfunction-Associated Steatohepatitis by Regulating Intrahepatic CD4⁺T Cell Immune Response
25 April 2026, Saturday	10:50 - 12:10	1071	ORAL PRESENTATION 55	Jishnu Jayarajan	Prevalence of significant fibrosis and metabolic correlates in patients with Metabolic dysfunction Associated Fatty Liver Disease: A cross-sectional study from a tertiary centre
25 April 2026, Saturday	10:50 - 12:10	1073	ORAL PRESENTATION 55	Soe Thiha Maung	Cognitive Impairment in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-analysis
25 April 2026, Saturday	10:50 - 12:10	1075	ORAL PRESENTATION 55	CLAUDINE FELICIANO	Effectiveness of Semaglutide in Non-Alcoholic Steatohepatitis resolution A meta-analysis and systematic review
25 April 2026, Saturday	10:50 - 12:10	1080	ORAL PRESENTATION 55	Sayfullo Avezov	Comparative Features of Viral and Metabolically Associated Liver Cirrhosis
25 April 2026, Saturday	10:50 - 12:10	1102	ORAL PRESENTATION 55	Jing Zhang	Natural History and Risk Factors of Metabolic Dysfunction–Associated Fatty Liver Disease in Chinese Cohorts: A Scoping Review
25 April 2026, Saturday	10:50 - 12:10	1139	ORAL PRESENTATION 55	Shamsul Mohd Zain	Sequential Application of the Fibrosis-4 Index and Serum Gamma-Glutamyl Transferase for Enhanced Detection of Advanced Fibrosis in Type 2 Diabetes Mellitus Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
25 April 2026, Saturday	10:50 - 12:10	1170	ORAL PRESENTATION 55	Angel Cho Kan Ma	Nurse-led lifestyle modification intervention to improve self-efficacy, illness perception, self-management behaviours and liver steatosis among adults with metabolic dysfunction associated steatotic liver disease: A pilot randomised controlled trial
25 April 2026, Saturday	10:50 - 12:10	1172	ORAL PRESENTATION 55	Linying Lai	EMMPRIN Loss Promotes Fatty Acid Transport Protein FATP2 Lactylation in MAFLD via the MCTs-lactate Axis
25 April 2026, Saturday	10:50 - 12:10	1973	ORAL PRESENTATION 56	Haiying Zhang	Prognostic Utility of baseline and SVR12/24 M2BPGi for Liver-Related Events in hepatitis C patients
25 April 2026, Saturday	10:50 - 12:10	1989	ORAL PRESENTATION 56	TALAL BHATTI	Post-Polypectomy Bleeding in Patients with Cirrhosis: A Systematic Review of Risk, Predictors, and Procedure-Related Factors
25 April 2026, Saturday	10:50 - 12:10	2006	ORAL PRESENTATION 56	Faruk Karakeçili	Phenotypic Pattern of Acute Liver Injury in Crimean-Congo Hemorrhagic Fever Among Patients with Chronic Hepatitis B in an HBV-Endemic Region
25 April 2026, Saturday	10:50 - 12:10	2168	ORAL PRESENTATION 56	Ghulam Mohiuddin	Colorectal Carcinoma in Young patients, single Centre study from Karachi, Pakistan.
25 April 2026, Saturday	10:50 - 12:10	2241	ORAL PRESENTATION 56	Serap Türk	Diagnostic Value of Liver Biopsy in Unexplained Liver Enzyme Elevations: A Tertiary Center Experience
25 April 2026, Saturday	10:50 - 12:10	2274	ORAL PRESENTATION 56	春润 李	Blood-Stasis Constitution Drives Hepatic MDSC Accumulation in MASLD
25 April 2026, Saturday	10:50 - 12:10	2326	ORAL PRESENTATION 56	Jacob George	Asia-Pacific expert consensus on GAAD for hepatocellular carcinoma surveillance
25 April 2026, Saturday	10:50 - 12:10	2398	ORAL PRESENTATION 56	Mark Siñagan	Etiology-Specific Patterns of Liver Stiffness and Steatosis Assessed by Transient Elastography in a Tertiary Referral Center in Southern Philippines
25 April 2026, Saturday	10:50 - 12:10	2450	ORAL PRESENTATION 56	Abdullah Tanrıkulu	A rare case: Sporadic Burkitt lymphoma presenting with high serum-ascite albumin gradient and low ascite glucose
25 April 2026, Saturday	10:50 - 12:10	1185	ORAL PRESENTATION 57	Vipul Gautam	Perioperative Management, Ethical Concerns, and Outcomes of Pediatric Domino Liver Transplants from Maple Syrup Urine Disease Donors
25 April 2026, Saturday	10:50 - 12:10	2390	ORAL PRESENTATION 57	Zhen Tian	Ultrasonographic evaluation of gallbladder motor function in the diagnosis and prognosis of intrahepatic cholestasis of pregnancy
25 April 2026, Saturday	10:50 - 12:10	2394	ORAL PRESENTATION 57	Deepa Janakiraman	Demystifying primary hepatic Langerhans Cell Histiocytosis (LCH)- From pattern recognition to molecular diagnosis
25 April 2026, Saturday	10:50 - 12:10	2499	ORAL PRESENTATION 57	Sindhuja Thatti Audikesavalu	Wilson disease mutation pattern with genotype-phenotype correlations in paediatric cohort in south India
25 April 2026, Saturday	10:50 - 12:10	2511	ORAL PRESENTATION 57	Kalpana Panda	Diagnostic accuracy of blood-based non-invasive tests for screening of varices in children with portal-hypertension: A systematic review and meta-analysis
25 April 2026, Saturday	10:50 - 12:10	2693	ORAL PRESENTATION 57	Jyoti Bhutani	Muscle Matters: Impact of Sarcopenia on Mortality and Clinical Outcomes in Pediatric Liver Transplantation
25 April 2026, Saturday	10:50 - 12:10	1196	ORAL PRESENTATION 57	Aizirek Abdikaiyrova	Prevalence and severity of chronic atrophic gastritis in cirrhotic patients versus dyspeptic controls
25 April 2026, Saturday	13:40 - 15:10	2506	ORAL PRESENTATION 58	Selma Tosun	Evaluation of anti-HCV positivity, HCV RNA testing, and treatment status among individuals presenting to the hospital
25 April 2026, Saturday	13:40 - 15:10	2507	ORAL PRESENTATION 58	Jeong-Ju Yoo	High Treatment Adherence Reduces HCC in Cirrhosis, with Additional Benefit from TAF Running title : Adherence Lowers HCC Risk in Cirrhosis
25 April 2026, Saturday	13:40 - 15:10	2510	ORAL PRESENTATION 58	Bei Jiang	Efficacy of PegIFNα Add-on Therapy in Treatment-Experienced CHB Patients with Low-Level Viremia: A Large Prospective Cohort Study
25 April 2026, Saturday	13:40 - 15:10	2514	ORAL PRESENTATION 58	Furkan Kırsoy	Long-term Clinical Outcomes of Delta Hepatitis in A Single Center Experience
25 April 2026, Saturday	13:40 - 15:10	2531	ORAL PRESENTATION 58	Velat AYTEKİN	Evaluation of Leptospirosis Cases in the Şanlıurfa Region
25 April 2026, Saturday	13:40 - 15:10	2533	ORAL PRESENTATION 58	Jidong Jia	Cross-study analysis of HBsAg rebound following treatments of elebsiran/BRII-179 in combination with peginterferon alfa
25 April 2026, Saturday	13:40 - 15:10	2560	ORAL PRESENTATION 58	Raad Rahmat	Predictive potential of hypermethylation of RASSF1A and CCND2 promoters in hepatitis B virus-induced hepatocellular carcinoma
25 April 2026, Saturday	13:40 - 15:10	2564	ORAL PRESENTATION 58	Yuyu Zeng	The relationship between the systemic immune-inflammation index and hepatitis C virus infection: NHANES 2005 to 2012
25 April 2026, Saturday	13:40 - 15:10	2576	ORAL PRESENTATION 58	Takako Inoue	Point-of-care HBcrAg testing to identify high viral replication in chronic hepatitis B: a tool for supporting the WHO simplified treatment strategy in resource-limited settings
25 April 2026, Saturday	13:40 - 15:10	1813	ORAL PRESENTATION 59	Johanna Lynne La Rosa-Rimorin	Unmasking the unknown: the unexpected discovery of hepatic epithelioid hemangioendothelioma
25 April 2026, Saturday	13:40 - 15:10	1837	ORAL PRESENTATION 59	Yan Zhou	Early Ablation for Sub-centimeter Hepatocellular Carcinoma: Divergent Outcomes in Primary vs Recurrent Tumors over 10 Years
25 April 2026, Saturday	13:40 - 15:10	1848	ORAL PRESENTATION 59	Daniele Alek Calda	Metastatic Liver Involvement from Primary Adamantinoma-like Ewing Sarcoma of the Lung in an Elderly Male: A Rare Case Presentation
25 April 2026, Saturday	13:40 - 15:10	1849	ORAL PRESENTATION 59	Huiwen Yan	Yangyin Fuzheng Jiedu Prescription Reduces Recurrence Risk in Patients with Small Hepatocellular Carcinoma after Minimally Invasive Treatment: a Pragmatic Randomized Controlled Trial
25 April 2026, Saturday	13:40 - 15:10	1851	ORAL PRESENTATION 59	Liang Zhang Zhang	Inhibiting PPM1D facilitates the phosphorylation and oligomerization of VDAC2 to elicit immunogenic tumor destruction by activating cGAS-STING-IFN response
25 April 2026, Saturday	13:40 - 15:10	1867	ORAL PRESENTATION 59	Tianyi Xia	Identification of benefit subgroups from heterogeneous effects of adjuvant transarterial chemoembolization in hepatocellular carcinoma using causal model
25 April 2026, Saturday	13:40 - 15:10	1890	ORAL PRESENTATION 59	Yaoyao Yu	Deep Learning CT Signature for Predicting Occult Liver Metastases and Neoadjuvant Therapy Benefit in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study
25 April 2026, Saturday	13:40 - 15:10	1899	ORAL PRESENTATION 59	Ying Lei	Exploring the value of imaging indicators in predicting TACE resistance in hepatocellular carcinoma based on contrast-enhanced CT
25 April 2026, Saturday	13:40 - 15:10	1906	ORAL PRESENTATION 59	Yuchan Xue	A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer
25 April 2026, Saturday	13:40 - 15:10	2019	ORAL PRESENTATION 60	Nurgul Toktogulova	Cardiometabolic Risks in Elderly Individuals With Fatty Liver Living in Mid-Mountain Regions of Central Asia
25 April 2026, Saturday	13:40 - 15:10	2023	ORAL PRESENTATION 60	Zhuoru Jiang	Impact of Liver Fat Contents on Brain Structure and Cognitive Functions in Patients with MASLD
25 April 2026, Saturday	13:40 - 15:10	2039	ORAL PRESENTATION 60	Clothilde Philouze	Modelling liver fibrosis and MASH with humanized immune system mice
25 April 2026, Saturday	13:40 - 15:10	2065	ORAL PRESENTATION 60	Yan Wang	Comprehensive multiomics study of ballooned hepatocytes in MASH: Insights into cellular adaptation to metabolic overload
25 April 2026, Saturday	13:40 - 15:10	2066	ORAL PRESENTATION 60	SHUN LI	Phenotypic Age is a Hepatocentric Marker of Biological Aging: Stronger Associations of Liver-Related and Metabolic Outcomes over Cardiovascular Events in Steatotic Liver Disease
25 April 2026, Saturday	13:40 - 15:10	2087	ORAL PRESENTATION 60	Yixue Shu	CD146 Regulates Hepatocyte Lipotoxicity through Modulation of Mitochondrial Energy Metabolism and Inflammatory Response
25 April 2026, Saturday	13:40 - 15:10	2110	ORAL PRESENTATION 60	Abdul Samad	THE RISING THREAT OF MASLD IN YOUNG ADULTS: A COMPREHENSIVE METABOLIC AND HEPATIC ASSESSMENT FROM SOUTH ASIA
25 April 2026, Saturday	13:40 - 15:10	2245	ORAL PRESENTATION 60	Kiavash Semnani	Unravelling the placebo response in pharmacological trials for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
25 April 2026, Saturday	13:40 - 15:10	2255	ORAL PRESENTATION 60	Muhammad Siddique Chohan	Role of Metabolic Risk Factors in the Early Detection of Metabolic-Associated Steatotic Liver Disease (MASLD) in Young Adults: A Cross-Sectional Study
25 April 2026, Saturday	15:30 - 17:00	1022	ORAL PRESENTATION 61	Hao Wang	SLC1A5-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration
25 April 2026, Saturday	15:30 - 17:00	1050	ORAL PRESENTATION 61	Ruifang Wang	Multicenter Study of Ultrasound-Guided Microwave Ablation for Hepatic Cystic Echinococcosis
25 April 2026, Saturday	15:30 - 17:00	2834	ORAL PRESENTATION 61	Ma. Angelica Goldamier Cannu	Epidemiologic and Clinical Trends in Hepatocellular Carcinoma: A Glimpse Through the Lens of Systemic Therapy Availability
25 April 2026, Saturday	15:30 - 17:00	2839	ORAL PRESENTATION 61	Jann Christian Solis	CAN EARLY CHANGES IN ALPHA-FETOPROTEIN PREDICT RADIOLOGIC RESPONSE AND OVERALL SURVIVAL IN IMMUNE CHECKPOINT INHIBITOR-BASED THERAPY OF HEPATOCELLULAR CARCINOMA?
25 April 2026, Saturday	15:30 - 17:00	2844	ORAL PRESENTATION 61	Yiming Wang	AARS1 promotes tumor progression and immune evasion via ATF6 lactylation–mediated tryptophan metabolism in hepatocellular carcinoma
25 April 2026, Saturday	15:30 - 17:00	2859	ORAL PRESENTATION 61	Dr.ANAND V KULKARNI	Profile of Hepatocellular Carcinoma in India: A Five-Year Prospective Study

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Session Date	Session Time	Abstract No	Session Name	Presenter Name	Presentation Title
25 April 2026, Saturday	15:30 - 17:00	2874	ORAL PRESENTATION 61	Jie Han	Dynamic evolution of the gut microbiome predicts therapeutic response in liver cancer: A large-scale longitudinal study with a cross-cohort meta-analysis
25 April 2026, Saturday	15:30 - 17:00	2876	ORAL PRESENTATION 61	DEEPAK JHA	Immune Checkpoint Inhibitor–Induced Hepatitis in HCC: Poor Response to Immunosuppression.
25 April 2026, Saturday	15:30 - 17:00	2877	ORAL PRESENTATION 61	Hikmet Akkız	The Effect of Portal Vein Tumor Trombosis on Survival in Patients with Hepatocellular Carcinoma Treated with Different Therapies
25 April 2026, Saturday	15:30 - 17:00	2647	ORAL PRESENTATION 62	Yang Yang	Quercetin ameliorates MASLD progression through the inhibition of the hexosamine biosynthesis pathway-mediated TAB2 protein O-GlcNAcylation
25 April 2026, Saturday	15:30 - 17:00	2664	ORAL PRESENTATION 62	Jiyuan Zhou	Integrating genetic omics and functional omics to identify clinically actionable gut microbiota–host interface targets in MASLD
25 April 2026, Saturday	15:30 - 17:00	2671	ORAL PRESENTATION 62	hang chen	Mechanistic Study of Resmetirom in Treating MAFLD Mouse Model: Gut Microbiota Remodeling and Metabolic Regulation
25 April 2026, Saturday	15:30 - 17:00	2714	ORAL PRESENTATION 62	Guanjing Lang	Exposure to Legacy and Replacement PFAS Is Associated with Metabolic Dysfunction–Associated Steatotic Liver Disease in Women
25 April 2026, Saturday	15:30 - 17:00	2759	ORAL PRESENTATION 62	da wang	α-KB downregulates miRNA-363-3p and targets SERCA2b to alleviate hepatic endoplasmic reticulum stress and steatosis in MAFLD
25 April 2026, Saturday	15:30 - 17:00	2762	ORAL PRESENTATION 62	Danielle Lucero	The Effects of Nomenclature Change on the Epidemiology of Fatty/Steatotic Liver Disease
25 April 2026, Saturday	15:30 - 17:00	2765	ORAL PRESENTATION 62	Muh syaiful akbar	Disability Adapted Digital Therapeutics as a Precision Strategy for MASLD Risk Modulation: Longitudinal Neuromuscular in Lower Limb Amputees
25 April 2026, Saturday	15:30 - 17:00	2773	ORAL PRESENTATION 62	QIQANQIAN ZHENG	Mechanistic Role of MFN2-FSP27 Mediated Lipid Droplet–Mitochondria Interactions in Metabolic Dysfunction-associated Steatohepatitis
25 April 2026, Saturday	15:30 - 17:00	2779	ORAL PRESENTATION 62	Ammar ALRAMADAN	Re-evaluation of Liver Biopsy Specimens Performed for Presumed Chronic Hepatitis B and Investigation of the Prevalence of MASLD
25 April 2026, Saturday	15:30 - 17:00	1642	ORAL PRESENTATION 63	Wen Zhao	Heme oxygenase-1 inhibiting mitochondrial apoptosis in metabolic associated fatty liver disease
25 April 2026, Saturday	15:30 - 17:00	1717	ORAL PRESENTATION 63	Miaomiao Tian	A new switch for lactate accumulation in metabolic dysfunction-associated steatotic liver disease
25 April 2026, Saturday	15:30 - 17:00	1729	ORAL PRESENTATION 63	Zilong Wang	The expression of Fmnl1 in monocyte-derived macrophages promotes hepatic inflammation in MAFLD
25 April 2026, Saturday	15:30 - 17:00	1732	ORAL PRESENTATION 63	Jian Zhao	Associations of sweetened beverages consumption with the risk of MASLD and its related outcomes across genetic risk profiles: a prospective population-based cohort study
25 April 2026, Saturday	15:30 - 17:00	1815	ORAL PRESENTATION 63	Qianli Zhao	Efficacy of Silybin Phospholipid Complex in Metabolic-Associated Fatty Liver Disease
25 April 2026, Saturday	15:30 - 17:00	1821	ORAL PRESENTATION 63	Tianyuan Yang	Adolescent MASLD Incidence Trends, 1990–2023: Global and National Perspectives
25 April 2026, Saturday	15:30 - 17:00	1908	ORAL PRESENTATION 63	Adinda Amalia	Performance of Baveno VII Criteria in Predicting Clinically Significant Portal Hypertension in Burned-Out MAFLD
25 April 2026, Saturday	15:30 - 17:00	1935	ORAL PRESENTATION 63	Yinuo Yang	Neuropilin-1 alleviates metabolic dysfunction-associated fatty liver disease by promoting lysosomal degradation of toll-like receptor 4 in macrophages
25 April 2026, Saturday	15:30 - 17:00	1945	ORAL PRESENTATION 63	Betül Tunç Demirci	Impact of Microbiome in Obese vs Lean Steatotic Liver Disease in Children
25 April 2026, Saturday	17:10 - 18:30	1356	ORAL PRESENTATION 64	Pengxuan Wu	Severe Hepatic Steatosis Impairs PEG-IFN Response in HBsAg Clearance-Favorable Chronic Hepatitis B: A Retrospective Cohort Study
25 April 2026, Saturday	17:10 - 18:30	1652	ORAL PRESENTATION 64	minshan huang	Investigating the Role of Gut Microbiota-Derived Valine in Treating MAFLD through PPAR Signaling
25 April 2026, Saturday	17:10 - 18:30	1965	ORAL PRESENTATION 64	Maurice Michel	Modeling the burden of steatotic liver disease and its subcategories in people living with HIV
25 April 2026, Saturday	17:10 - 18:30	2172	ORAL PRESENTATION 64	Alaa M. Mostafa	The coexistence of MAFLD exacerbates liver fibrosis in patients with chronic hepatitis B.
25 April 2026, Saturday	17:10 - 18:30	2336	ORAL PRESENTATION 64	Farhana Kayani	Lean MAFLD in Chronic Hepatitis B: Clinical Characteristics, Fibrosis Risk and antiviral response in a Pakistani Cohort
25 April 2026, Saturday	17:10 - 18:30	2340	ORAL PRESENTATION 64	Jalal Khan	Metabolic Fatty Liver Masks Hepatitis B Activity: Implications for ALT-Based Treatment Decisions, a study from PAkistan
25 April 2026, Saturday	17:10 - 18:30	2897	ORAL PRESENTATION 64	Yichen Peng	Integrative Metabolomic and Cytokine Profiling Reveals a "Metabolic-Inflammatory" Signature in Chronic Hepatitis B Combined with Metabolic Dysfunction-Associated Fatty Liver Disease
25 April 2026, Saturday	17:10 - 18:30	1459	ORAL PRESENTATION 64	Meti Metiani	Revisiting HepaScore: New Evidence for Non-Invasive Fibrosis Assessment in Indonesian Patients with Chronic Hepatitis B
25 April 2026, Saturday	17:10 - 18:30	1461	ORAL PRESENTATION 65	Chuyue Xiong	A Retrospective Study on PD-1/CTLA-4 Bispecific Antibody Therapy Promoting Partial Functional Cure of Hepatitis B in Patients with HBV-Related Hepatocellular Carcinoma
25 April 2026, Saturday	17:10 - 18:30	1466	ORAL PRESENTATION 65	Yijing Cai	A new prediction model based on plasma ammonia and the Chinese Group on the Study of Severe Hepatitis B-ACLF-Ⅱ score for patients with Hepatitis B virus-related acute-on-chronic liver failure.
25 April 2026, Saturday	17:10 - 18:30	1472	ORAL PRESENTATION 65	Xiaoman Liu	Divergent immune resolution and protracted immuno-metabolic memory in hepatitis E revealed by cross-species multi-omics
25 April 2026, Saturday	17:10 - 18:30	1517	ORAL PRESENTATION 65	Fatma Merve Kocak	Hepatitis B serology and vaccine response in uveitis patients treated with adalimumab: effects of the 1998 national hepatitis B vaccination program in Turkey
25 April 2026, Saturday	17:10 - 18:30	1525	ORAL PRESENTATION 65	Yuelong Lin	A Multi-Sectoral Co-Payment Model to Reduce Hepatitis C Treatment Costs and Advance Elimination Among Low-Income Populations: Experience from Yangjiang, China
25 April 2026, Saturday	17:10 - 18:30	1526	ORAL PRESENTATION 65	Yanfei Feng	Transcriptional Activity of cccDNA in HBsAg-Negative Individuals with a History of Hepatitis B Virus Infection
25 April 2026, Saturday	17:10 - 18:30	2649	ORAL PRESENTATION 65	Jie Bai	Microsomal Glutathione S-Transferase 2 Links Copper Toxicity to Hepatic Inflammation via Leukotriene C4 in Wilson's Disease
25 April 2026, Saturday	17:10 - 18:30	2871	ORAL PRESENTATION 65	KRISHNAKANTH SARDA	Genetic Variants in Bile Transporter Genes in Prolonged Cholestatic Jaundice Associated with HAV and Drug-Induced Liver Injury
24 April 2026, Friday	09:00 - 10:30	1121	ORAL PRESIDENTIAL SESSION	Xingru Wang	The first application and feasibility assessment of 5G-enabled remote robot-assisted hepatobiliary and pancreatic surgery in patients with malignant tumors
24 April 2026, Friday	09:00 - 10:30	1380	ORAL PRESIDENTIAL SESSION	Mengmeng Zhang	The SAFE-DILI Model for the Dynamic Prediction of Liver Transplantation or Death in Idiosyncratic Drug-Induced Liver Injury
24 April 2026, Friday	09:00 - 10:30	1587	ORAL PRESIDENTIAL SESSION	Qinshuo Wang	Remodeling of the bile acid connectome across the hepatitis-cirrhosis-hcc axis: network analysis reveals stage-specific hubs and potential therapeutic targets
24 April 2026, Friday	09:00 - 10:30	2130	ORAL PRESIDENTIAL SESSION	Ju Dong Yang	Predictors and impact of complete pathological response to pre-transplant immune checkpoint inhibitors in hepatocellular carcinoma: Findings from the Global LIFT-HCC consortium
24 April 2026, Friday	09:00 - 10:30	2505	ORAL PRESIDENTIAL SESSION	Cihan Yurdaydin	Lonafarnib as finite treatment for chronic hepatitis D: Long-term follow-up data